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Idiopathic Inflammatory Myopathies (IIMs) are a heterogeneous group of acquired 
diseases characterised by inflammation of the skeletal muscle. The most common 
forms are sporadic inclusion body myositis (sIBM), dermatomyositis, polymyositis, 
overlap syndormes and necrotising myopathy. Sporadic IBM is the most common 
acquired myopathy over the age of 50 years, however its pathogenesis remains 
largely unsolved and there is still debate on whether it is a primary inflammatory or a 
degenerative condition with secondary inflammatory component. I used an in silico 
approach to identify molecules of interest that might shed light on the pathogenesis 
of sIBM. Emerin, a nuclear envelope protein, resulted as one of the candidate 
molecules.  
To verify in silico analysis results I reviewed a cohort of patients with sIBM 
phenotype identified at Charing Cross Hospital. This review allowed me to select 10 
sIBM patients and identify 3 further patients with sIBM-like phenotype and good 
response to steroids. The selected patients have been then tested through 
immunohistochemical, immunoblotting and sequencing studies. 
Immunohistochemistry studies using anti-emerin antibodies showed abnormal 
distribution of emerin in the sIBM patients but not in the 3 patients with sIBM-like 
phenotype. Interestingly, sequencing of the emerin gene identified missense 
mutations in the 5’-untranslated region.  
The three IBM-like patients were extensively studied and serum analysis allowed me 
to identify a novel autoantibody that proved to target the sarcoglycans. Sequencing 
of the sarcoglycans genes in the three patients identified a missense mutation in the 
β-sarcoglycan affecting the 3D-structure of the extracellular component. The 
identification of this novel autoantibody prompted a further pilot study to develop a 
diagnostic test to identify novel autoantibodies to sarcolemmal proteins. Variable 
positive reactivity against sarcolemmal proteins, suggestive of presence of 
autoantibodies against sarcolemmal proteins was identified through immunoblotting 
in the sera of 10 further IIM patients, but not in 9 controls.  
This study highlights the complexity behind the pathogenesis of IIM and importance 
of unified classification criteria. Although further studies on a larger scale will be 
needed I suggest that emerin immunolabeling could be used as diagnostic biomarker 
in patients with sIBM. In addition, a pilot study using of skeletal muscle protein 
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extract revealed novel autoantibodies in IIM whose pathogenicity remains to be 
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Idiopathic Inflammatory Myopathies (IIMs) are a heterogeneous group of acquired 
diseases characterised by inflammation of the skeletal muscle. They are part of a 
major class of muscle diseases called Inflammatory Myopathies (IM). IMs are divided 
in two main categories: infective and idiopathic (or autoimmune) (Mastaglia, 2008). 
The infective forms can be caused by viral, bacterial, fungal, protozoal or helminthic 
infection; the autoimmune IM are further divided in generalized and focal forms 
(Mastaglia, 2008). The generalized forms include following conditions: sporadic 
inclusion body myositis (sIBM), dermatomyositis (DM), polymyositis (PM), overlap 
syndormes, necrotising myopathy, eosinophilic myositis and granulomatous myositis 
(Mastaglia, 2008). The focal forms include the localized nodular myositis, monomelic 
myositis, angiopathic myositis, eosinophilic myositis, macrophagic myofascitis, 
inflammatory pseudotumour and orbital myositis. IIMs are a heterogeneous group of 
acquired conditions and are characterised by inflammatory infiltrate in muscle fibres 
and variable upregulation of major histocompatibility complex-I (MHC-I) and 
degenerative changes in the muscle fibres (Dubowitz & Sewry, 2006). They involve 
mainly the skeletal muscle, and patient usually shows predominant proximal muscle 
weakness but other organs may be involved during the acute or chronic phase of the 
disease. Creatine kinase (CK) is usually elevated. The most common forms are PM, 
DM and sIBM (Cox et al, 2010). Although the different forms of inflammatory 
myopthies have some common features, they have distinct clinical and pathological 
features and a correct diagnosis is crucial for prognosis and treatment.  
Wagner first described myositis in 1863; the first case of DM was documented in 
1875 by Potain and in 1886 Unvericht described the first case of PM (Oddis & 
Medsger, 1995; Bohan, 1988) while sIBM was recognised only in late 1967 by Chou 
(Chou 1967).  
Over the past 40 years authors have suggested various diagnostic criteria and 
classifications (Medsger 1970; DeVere & Bradley 1975; Bohan & Peter 1975; Targoff 
1997; Dalakas & Hohlfeld, 2003; Pestronk 2011) with the most widely used criteria 
being those proposed by Bohan & Peter in 1975. However, the scientific community 
has not yet agreed and approved a worldwide classification for IIM.  Over the years 
classification criteria were variably based on clinical and histological features, 
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laboratory findings; these include muscle weakness, elevated muscle enzymes [CK, 
lactate dehydrogenase (LDH), aldolase], myopathic features on electromyography 
(EMG) and muscle biopsy (Cox et al, 2010). The classification proposed by Bohan 
and Peter in 1975 divides inflammatory myopathies into 5 groups (PM, idiopathic 
DM, PM-DM associated to tumour, juvenile PM-DM and PM-DM associated to other 
connective tissue disease or overlap syndrome). Although widely used, this 
classification has never been validated and has recently been reviewed by Dalakas 
and Hohlfeld (2003) with the inclusion of sIBM. The new criteria include 
immunopathological features and point out the role of the MHC-I antigen and of 
cytotoxic CD8 positive T-cells as specific markers that help differentiating antigen-
mediated inflammatory response, typical of PM and sIBM, from secondary non-
specific inflammatory response of other muscular diseases like muscular dystrophies 
and genetic determined myopathies (Briani et al., 2006). Although the classification 
proposed by Bohan and Peter criteria (Bohan & Peter, 1975) is the most widely 
used, recent studies demonstrated that its specificity is very low (29%) compared to 
new ones, and the classification criteria proposed by Dalakas (Dalakas & Hohlfeld, 
2003) have the highest specificity (99%) (Linklater et al, 2013). Furthermore, the 
Bohan and Peter criteria often can lead to misdiagnose PM from sIBM or some types 
of muscular dystrophies (Dalakas & Hohlfeld, 2003).  
Over the years, thanks to the identification of myositis specific antibodies (MSA) and 
myositis associated antibodies (MAA) new classifications have been proposed based 
on the serological status of the patient (Love et al 1991, Troyanov et al, 2005). MSA 
are autoantibodies that target either nuclear or cytoplasmic cell components and are 
highly selective and usually characteristic of a particular IIM clinical phenotype 
(Targoff, 2008). Based on this new criteria suggested by Love in 1991 patients were 
classified according Bohan and Peter’s classification with the inclusion of sIBM and 
taking into account their serological status (Love et al 1991). Troyanov, years later, 
suggested a similar classification based on revised Bohan and Peter criteria with the 
inclusion of overlap myopathies (Troyanov et al, 2005). This classification is thought 
to have high sensitivity (87%) when used to identify overlap syndrome (Troyanov et 
al, 2005). In the last few years Pestronk proposed another classification using 
myopathologic features as guidelines for IIM classification (Pestronk, 2011).  
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Although Bohan and Peter’s classification criteria are nowadays considered obsolete 
due to low sensitivity and specificity compared to all the new classifications that have 
been proposed in more recent years (Linklater et al, 2013), an agreement has yet to 
be reached by the scientific community and classification criteria have to be 
validated.  
As a result of variability and non-unanimity of classification criteria a precise 
estimation of epidemiology of IIM and of its subtypes is very difficult. The 
approximate reported annual incidence ranges from 2 – 8 cases per million people 
per year (Oddis et al 1990, Benbassat et al 1980, Weitoft et al 1997, Koh et al 1993). 
Overall, it appears that DM is the most common with an incidence of 8 cases/million 
population/year, PM less frequent with 4 cases/million population/year and sIBM the 
most frequent in the older population. The prevalence of sIBM is estimated to be 4.3-
9.3 per 1 000 000 before the age of 50 years but 35.3 per 1 000 000 in the 
population over the age of 50 years (Mastaglia & Phillips, 2002; Engel & Askanas, 
2006; Needham et al, 2008). PM and DM affect females more commonly with a ratio 
male/female of [1:2], while sIBM is more common in male with a male/female ratio of 
[3:1] (Prieto & Grau, 2010; Dimachkie et al, 2014). A geographic variability of the 
incidence of PM and DM has been observed throughout the years which is mainly to 
be attributed to differences in diagnostic criteria that have been applied to reach or 
define the diagnosis (Cox et al, 2010).  
IIMs share some clinical and pathological features such as progressive muscular 
weakness, raised CK, dysphagia, inflammatory infiltrate, various degenerative 
changes in the muscle fibres and sarcolemmal upregulation of MHC-I. However, they 
also have distinct characteristics, which help to distinguish the various forms and 
possibly achieve a final diagnosis; these will be described in the next section.  
Since this study focuses on sIBM and PM/DM as controls, these three conditions will 
be described into more detail. 
 
Dermatomyositis and juvenile Dermatomyositis 
Dermatomyositis is a microangiopathy and is characterised by a disease onset in 
adult life with sub-acute, symmetric proximal muscle weakness and extra-muscular 
manifestations, typically there is skin rash. CK is usually raised at up to 50 times the 
normal values (Dimachkie & Barohn, 2012). Electromyography shows polyphasic 
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motor unit action potentials of short duration and low amplitude on voluntary 
contraction with increased insertional and spontaneous activity, fibrillation potentials, 
sharp waves and/or repetitive discharges (Ernste & Reed, 2013).  
DM can occur in association with skin changes, or skin changes without myositis 
(DM sine myositis or amyopathic DM), and in the absence of skin changes a 
diagnosis of possible DM sine dermatitis can be raised based on histopathological 
findings and other clinical criteria with exception of skin rash. Skin changes are most 
commonly characterised by erythematous and photosensitive heliotrope rash which 
involves face, neck, anterior chest (V-neck sign) or upper back (shawl sign) and 
extensor surface of arms; violaceous papules (Grotton’s papules) or macules 
(Grotton’s sign) can be found at metacarpophalangeal and interphalangeal joints. In 
severe cases skin goes under dramatic changes becoming tight, shiny and reddened 
(Dubowitz & Sewry, 2006). Apart from skin changes there can be involvement of 
other organs; pulmonary, gastrointestinal and cardiovascular systems may be 
affected. Typically patients can present with interstitial lung disease (ILD), dysphagia 
and myocarditis or arrhythmias (Briani et al 2006).  
DM can occur in association with malignancies or other autoimmune conditions and 
mixed connective tissue disorders. The risk of malignancies appears to be in the five 
years preceding the presentation of the disease and in the first five years following 
the diagnosis (Mastaglia, 2008). Malignancy seems to occur in at least 25% of adult 
patients within the five years preceding diagnosis. Tumours that are most commonly 
found in association with DM are breast and ovarian cancer in women and prostate 
and lungs cancer in men (Ernste & Reed, 2013). Presence of autoantibodies anti-
p155/140 in DM patients is associated with malignancy (Betteridge et al 2009, 
Gunawardena et al, 2009).  
Histopathological findings are characterised by variation in fibres size, internal nuclei, 
necrotic fibres, perifascicular atrophy, perimysial and perivascular infiltration of CD4 
positive T-cells (Dalakas & Hohlfeld, 2003). Deposits of membrane attack complex 
(MAC) are found on capillaries and sarcolemma as well as up-regulation of MHC-I 
on capillaries and sarcolemma in the perimysium; notably there is a reduction of the 




Juvenile DM is the paediatric counterpart of DM and has an onset between 5 and 15 
years old (Boccaletti et al, 2014). In addition to the skin rash and weakness, some 
children develop as well calcinosis and contractures. Disease severity can vary from 
milder forms to severe and life threatening disease manifestations. In contrast to DM, 
the association with malignancy is uncommon in children (Ernste & Reed, 2013). 
 
Polymyositis usually affects the adult population after the second decade of life 
and is very rarely seen in the paediatric population. PM is a subacute inflammatory 
myopathy that progresses over weeks to months with proximal upper and lower limb 
muscle involvement; distal weakness, dysphagia and facial weakness can also occur 
(Dimachkie et al, 2014). Compared to DM and sIBM, it is the least frequent and often 
misdiagnosed as sIBM. The diagnosis of PM is based on exclusion of skin rash, 
family history for neuromuscular disorders, exposure to myotoxic drugs, endocrine 
disease, neurogenic disease, muscular dystrophies and metabolic myopathies and 
sIBM. CK serum level is raised up to 50x the normal upper limit (van der Meulen et 
al, 2003; Dimachkie et al, 2014).  
PM frequently occurs in association with other autoimmune and connective tissue 
disorders, and sometimes with malignancies with an approximate frequency of 10-
15%, however the latter one is less compared to DM (Ernste & Reed, 2013). The 
muscle biopsy shows variation in fibres size, internal nuclei, necrotic fibres, 
regenerating fibres, and endomysial inflammatory infiltrate with invasion of non-
necrotic fibres. The inflammatory infiltrate is mainly composed by CD8-positive 
cytotoxic T-cells invading MHC-I expressing muscle fibres (Dalakas, 2011). No 
deposits of complement, MAC or immunoglobulins are found in the 
microvasculature.  
Pestronk described a novel form of PM, which they called PM-mito, a subtype of IM 
with vacuoles, aggregates and mitochondrial pathology (IM-VAMP) (Temiz et al, 
2008; Pestronk, 2011). PM-mito is a slowly progressive inflammatory myopathy with 
onset typically above the age of 60 years, affecting predominantly quadriceps, wrist, 
finger flexors and knee extensors (Temiz et al, 2008). Histopthological features are 
endomysial and perivascular inflammatory infiltration composed mainly of CD4-
positive and CD8-positive T-cells. Other histopathological features include irregular-
  
12 
shaped vacuoles with basophilic granular debris, cytoplasmic myofibre aggregates 
which may contain phosphorylated proteins and amyloid, abnormal myonuclei and 
mitochondrial abnormalities such as mtDNA deletions. In PM-mito mtDNA deletions 
are about 90% (Pestronk, 2011) and fibres are frequently COX-negative (Chahin and 
Engel, 2008). Patients with less than 10% of COX negative fibres respond better to 
methotrexate treatment while usually there is poor response to corticosteroid 
treatment (Temiz et al, 2008). 
 
Sporadic IBM is the most common acquired myopathy over the age of 50 years 
and affects men more commonly than women with a ratio [3:1]. 
In the past 20 years various studies have ananlysed previously published criteria and 
in order to achieve consensus on diagnostic criteria for sIBM (Rose et al 2013; Lloyd 
et al, 2014) and revised diagnostic criteria have been proposed: ENMC IBM 
Research Diagnostic Criteria 2011 (Rose et al, 2013). Based on these criteria sIBM 
can be defined as clinico-pathological IBM, clinical defined IBM or probable IBM 
depending on number of clinical and laboratory features present (Rose et al, 2013). 
Clinical features include slowly progressive weakness and wasting of the distal and 
proximal muscles and early involvement of quadriceps and finger flexors; CK is 
usually normal or slightly increased. Typically patients with sIBM do not respond to 
treatment (Dalakas, 2006; Needham & Mastaglia, 2008). In contrast, PM and DM 
cause symmetrical non-selective proximal myopathy and are generally steroid 
responsive. Muscle biopsy is essential for the diagnosis and is characterised by 
multifocal endomysial inflammatory infiltrates composed of CD8-positive cells but 
also of B-cells and plasma cells, rimmed vacuoles (RVs) in fibres not invaded by 
lymphocytes, sarcoplasmic inclusions, ragged red-fibres, COX-negative fibres and 
ubiquitous expression MHC class I antigen (Dalakas 2006; Needham & Mastaglia 
2008). Electron microscopy (EM) reveals prominent myonuclear changes including 
irregular nuclear profiles and intranuclear filamentous 7 nm inclusions. Furthermore 
EM reveals accumulation of tubulo-filamentous inclusions (15-21 nm) and 
cytoplasmic amyloid-like filaments (6-10 nm) (Askanas & Engel, 2003). 
The association between sIBM and human leukocyte antigen genes, DRβ1*0301 
and DQβ1*0201 alleles, confers susceptibility to sIBM. The B8-DR3-DR52-DQ2 
haplotype is found in 67% of sIBM patients and is associated with earlier disease 
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onset (Koffman et al., 1998; Badrising et al., 2004; O’Hanlon et al, 2005; Mastaglia et 
al., 2009). 
The pathogenesis of sIBM remains still unknown. In the past 40 years several 
theories regarding the pathogenesis of sIBM have been raised, but it is still unclear 
whether sIBM is primarily a T-cell mediated inflammatory myopathy like PM, or a 
myodegenerative disorder with abnormal protein aggregations responsible for a 
secondary inflammatory response (Finch 2006; Needham & Mastaglia 2008). 
Several hypotheses have been suggested to explain its pathogenesis ranging from 
viral infection to autoimmune or degenerative origin (Benveniste et al 2015). Many 
studies have suggested pathological similarities between sIBM and 
neurodegenerative diseases such as Alzheimer’s disease (Finch, 2006; Needham & 
Mastaglia, 2008).  
Several studies have suggested that a viral infection may act as a trigger to develop 
sIBM, although molecular techniques have failed to confirm presence of any viruses 
in muscle. This hypothesis is supported by several reports of patients with retroviral 
infection (HIV or HTLV-1) and associated sIBM (Cupler et al., 1996; Ozden et al., 
2004; Saito et al., 2002; Dalakas, 2006; Dalakas et al., 2007). Clonally in situ 
expanded CD8-positive T-cells that invade MHC-I positive muscle fibres were found 
to be retrovirus specific as amino acid residues of the CDR3 region were specific for 
viral peptides bound to HLA. It was hypothesised that the viral infection followed by 
immune response might be responsible for the chronic inflammatory process leading 
IBM clinico-pathological features (Dalakas, 2011).  
Various authors support the hypothesis of a primary autoimmune origin in sIBM, 
suggesting that the inflammatory component is more prominent in the early stage 
rather than late stage of the disease when the degenerative component 
predominates. The endomysial inflammatory cells are predominantly CD8-positive T-
cells (Dalakas, 1998), which are clonally expanded with a restricted T-cell receptor 
(Müntzing et al., 2003). Plasma cells have also been described as part of the 
inflammatory infiltrate and immunoglobulin transcripts have been demonstrated with 
microarray studies (Greenberg et al., 2005; Raju & Dalakas, 2005).  
In the last years the role of B cells in the pathogenesis of sIBM has gained 
importance. Their role in the inflammatory component of other IIM is well known and 
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in recent years researchers demonstrated overexpression of a number of 
immunoglobulin genes together with CD138 positive plasma cells in muscle tissue 
(Greenberg et al, 2002; Bradshaw et al, 2007). The typical maturation environment 
of B cells is the lymphoid germinal centre in the lymphoid tissue, which is composed 
of abundant follicular dendritic cells and B cell follicles (Salajegheh et al, 2010). Due 
to the instability of RNA transcripts, the presence of immunoglobulin transcripts in 
the muscle could be due only to local cellular production (and not to deposition from 
circulation) (Greenberg et al, 2005); it has been suggested that this could be 
attributed to a permissive environment for local B cell maturation in muscle. Regions 
of dense B cells infiltrates have been described both in perimysial areas around or 
near large blood vessels and in endomysial regions. These infiltrates called “nodular 
infiltrates”, contained also T cells (CD3 positive), myeloid dendritic cells (BDCA1 
positive) and CD138- positive plasma cells (Salajegheh et al, 2010). The presence of 
myeloid dendritic cells has been confirmed thanks to further analyses by Greenberg 
who has demonstrated that they surround and sometimes invade non-necrotic 
myofibre regions (Greenberg et al, 2007). There, naïve B cells mature into antibody-
producing plasma cells thus transforming the muscle in an immune cell host where 
plasma cells and myeloid dendritic cells activate T-helper cells (Greenberg, 2007; 
Salajegheh et al, 2010). Moreover, the abundance of immunoglobulin gene 
transcripts in the muscle correlates well with the presence of visible nodular 
infiltrates (Salajegheh et al, 2010). Microarray mRNA expression studies on sIBM 
documented up-regulation of genes associated with immunoregulatory pathways, 
cell adhesion molecules and the cytoskeletal network in sIBM, but failed to identify 
an expression profile that is characteristic of sIBM (Raju & Dalakas, 2005; 
Greenberg et al, 2005; Greenberg 2007; Parker et al 2009). 
Further studies of clonal expansion, immunoglobulin isotype usage and somatic 
mutations in sIBM and PM muscle tissue have demonstrated the presence of 
antibodies in sIBM and PM patients’ sera (Targoff, 1993) supporting the hypothesis 
of an antibody-mediated autoimmunity as a response to an unknown antigen. B cells 
in the muscle tissue are clonally expanded and it has been observed that most of 
them had switched from IgM to either IgG or IgA. This is peculiar because usually 
naïve resting B cells do not class switch till the encounter with an antigen, which 
means that these cells are mature and have become plasma cells. These cells had 
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also undergone somatic mutations which supported the antigen-driven response 
hypothesis. Another finding in support of this theory is the presence of common 
amino acid mutations in unrelated B cells clones, probably due to the recognition of a 
common antigen (Bradshaw et al, 2007). 
Recently, Salajegheh et al. (2011) identified autoantibodies against a 43 kDa antigen 
in 52% of the patients with sIBM. This finding was then confirmed in two other 
separate studies, which showed autoantibodies to cytosolic 5'-nucleotidase 1A (anti-
cN1A) in sIBM (Larman et el, 2013, Pluk et al 2013). However, so far this newly 
identified antibody does not seem to be solely present in sIBM but was identified at a 
lower frequency also in other subtypes of IIM (Pluk et al, 2013).  In sIBM, MHC-I 
antigen is almost ubiquitously expressed on sarcolemma and sarcoplasm, which is in 
normal conditions not expressed on muscle fibres. In some other conditions, even in 
muscular dystrophies MHC-I can be up regulated in some degenerating or 
regenerating fibres. The exact mechanism of MHC-I up-regulation is still unknown 
and it is thought that its up-regulation could be induced by cytokines. Chronic up-
regulation of MHC-I might in turn induce endoplasmic reticulum stress (Nagaraju et 
al., 2005; Dalakas, 2006).  
A degenerative process with secondary inflammatory response has also been 
hypothesised as being the cause for sIBM. Evidence for a degenerative process in 
sIBM is provided by the presence of RVs and the intracellular deposition of proteins 
such as tau, β-amyloid, αΒ-crystallin and TDP43 and oxidative stress proteins.  In 
addition, proteasomal abnormalities and dysfunction has been documented and 
reported in sIBM leading to accumulation of unfolded and misfolded proteins (Fratta 
et al 2005). Disrupted myonuclear structure, intranuclear filamentous inclusions and 
the presence of emerin and histone1 in RVs are also features of sIBM that suggest a 
role of nuclear proteins in this condition but little emphasis has been given to these 
findings (Karpati and Carpenter 1993; Askanas & Engel, 2003; Greenberg et al, 
2006; Fidzianska et al, 2008; Nakano et al, 2008; Nishii et al, 2011). Greenberg et al 
(2006) showed that RVs were lined with emerin and lamin A/C, further to this they 
also showed with the use of immunohistochemistry and EM focal rupture of 
myonuclear membranes. In particular Nakano et al (2008) demonstrated presence of 
histones H1, emerin and DNA in sIBM RVs and Nishii et al (2011) demonstrated 
increased percentage of DNA double strand breaks in sIBM myonuclei and defects 
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of nuclear translocation of Ku70 protein that is responsible for DNA double strand 
break repair. However the etiopathogenesis of sIBM still remains largely object of 
controversy.  
Serology of Myositis  
 
In recent years there is increasing evidence of a relationship between genotype, 
serotype and clinical phenotype in IIM (Love et al, 1991; Targoff, 2008; O’Hanlon et 
al, 2005).  
Autoantibodies detected in patients with IIM are classified in MSA and MAA and a 
high-titre autoantibody is found in 50% - 80% of myositis patients (Betteridge et al 
2009; Gunawardena et al, 2009). MAA are mainly found in patients with other 
connective tissue disorders and can be found in overlap syndromes while MSA are 
usually highly selective, mutually exclusive and are characteristic of a particular IIM 
clinical phenotype; in general they are not found in other types of connective tissue 
disorder.  
MSA have been reported to be associated with particular genotypes (Chinoy et al, 
2009; 2011). MSA target either nuclear or cytoplasmic cell components, which may 
have a role in gene transcription, protein translocation and even in anti-viral 
responses.  
Serological status of patients with IIM has gained increasing role over years and 
autoantibodies have now been included in the classification criteria (Troyanov et al, 
2005) and are being used as diagnostic biomarkers to achieve a diagnosis and guide 
pharmacological treatment (Targoff, 2006).  
 
Myositis Specific Autoantibodies (MSA)  
 
• Anti-aminoacyl-tRNA synthetase (anti-ARSs):  
 anti-Jo1 (anti-histidyl synthetase)  
 anti-PL7 (anti-threonyl synthetase)  
 anti-PL12 (anti-alanyl synthetase)  
 anti-EJ (anti-glycyl synthetase)  
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 anti-OJ (anti-isoleucyl synthetase)  
 anti-KS (anti-asparaginyl synthetase)  
 anti-Ha (anti-tyrosyl synthetase)  
 anti-Zo (anti-phenyalanyl synthetase)  
 
• Anti-SRP (signal recognition particle)  
• Anti-Mi-2  
• Anti-CADM-140/MDA5  
• Anti-p155/140  
• Anti-p140  
 
Anti-ARSs are directed against a group of cytoplasmic enzymes that catalyses the 
binding of specific amino acids to their respective tRNA (Gunawardena et al, 2009). 
Anti-ARS are the most common MSA in both PM and DM and are predominantly 
found in the adult myositis patients (Targoff, 2006; Gunawardena et al, 2009). 
Patients typically have a unique clinical picture known as antisynthetase syndrome 
which is characterised by muscle weakness and pain, ILD, fever, mechanic hands 
and non-erosive arthritis. These symptoms can present individually or associated 
depending on which anti-ARS has been identified in the patient.  
The reason why ARS are targeted as autoantigens is still unknown. However, it has 
been demonstrated that the epitope recognized by the autoantibodies is located at 
the N-terminus of the proteins (Park et al, 2008). These autoantigens tend to cluster 
on the surface of apoptotic cells when cell death is induced by granzyme B which 
then cleaves the autoantigens into fragments (Casciola-Rosen et al, 1994). They 
have chemoattractant properties through CCR3 and CCR5 receptors expressed by 
leukocytes. The continuous production of these autoantigens associated with 
chemoattractant activity may lead to the spreading of inflammation in muscle 
(Betteridge, Gunawardena et al, 2009).  
Association with some forms of cancer has also been described, particularly for 
mutations in isoleucyl-tRNA synthetase that are associated with hereditary non-
polyposis colon cancer (HNPCC) and for mutations in phenylalanyl-tRNA synthetase 
which have been reported in lung solid tumours and acute phase chronic leukaemia 
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(Park et al, 2008).  
 Anti-Jo1 antibodies were first described in 1980 and are the most common 
of the anti-ARS antibodies; they are detected in about 25-30% of the patients 
with myositis and in 60-70% of patients with ILD.  
Increased expression of anti-Jo1 autoantibody has been demonstrated in 
regenerating fibres, supporting the hypothesis that production of these 
autoantigens during regeneration attempt may induce a propagation of the 
autoimmune response (Betteridge, Gunawardena et al, 2009). However, it is 
unlikely that these are disease causative since they are normally not 
expressed in adult muscle apart during regeneration. 
 
 Anti-PL7, anti-PL12, anti-EJ, anti-OJ, anti-KS, anti-Ha and anti-Zo 
antibodies collectively may be detected in about 20% of PM and DM patients 
and individual frequency ranges from 1 to 5 % (Betteridge et al, 2007; 
Gunawardena et al, 2008).  
 
Anti-Signal Recognition Particle (anti-SRP) antibodies target a highly conserved 
RNP complex (proteins - 7SLRNA), which is responsible for regulation of protein 
translocation through the endoplasmic reticulum (Ghirardello et al, 2013). Anti-SRP 
autoantibodies are detected in approximately 5% of IIM patients. Usually patients 
can have a severe myopathy with an acute onset and high CK level; other features 
include dysphagia which can be also refractory to treatment, severe cardiac 
involvement can also occur and is associated to poor survival (Targoff, 2006; 
Gunawardena et al, 2009).  
 
Anti-Mi-2 antibodies target a nuclear helicase protein that is part of the 
nucleosome-remodelling deacetylase (NuRD) complex which is involved in gene 
transcription (Gunawardena et al, 2009). Mi-2 acts together with other component of 
the NuRD complex as a transcriptional suppressor; however it is also involved 
through its N-terminus domain in transactivating proteins. Anti-Mi-2 antibodies are 
detected in approximately 9% of patients with myositis and in approximately 20% of 
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patients with DM. It was found that Mi-2 protein expression in keratinocytes 
increases following UV exposure and it was suggested that this triggers anti-Mi-2 
production in UV-induced dermatitis (Betteridge et al, 2009; Gunawardena et al, 
2009). Although patients with anti-Mi-2 appear to have more severe cutaneous 
symptoms, prognosis usually is favourable and there is a good response to 
corticosteroid treatment. In addition, myositis associated with anti-Mi-2 has a lower 
incidence of malignancy compared to forms of IIM (Troyanov et al, 2005; Mammen, 
2010).  
 
Anti-CADM-140/MDA5 antibodies target a cytoplasmic 140 kD protein called 
melanoma-differentiation associated gene 5 (MDA5) which is involved in innate 
immune-responses against viral infections (Sato et al, 2013; Silveira et al, 2015). 
Anti-CADM-140/MDA5 antibodies have been identified in patients with clinically 
amyopathic DM and are predominantly found in the Japanese and US DM 
population. Usually these patients do not present any or little muscle involvement, 
however are at increased risk of developing rapidly progressive ILD (Sato et al, 
2013; Labrador-Horillo et al, 2014; Silveira et al, 2015).  
 
Anti-p155/140 antibodies target a 155 kD and 140 kD proteins which are believed 
to be the same protein. Anti-155/140 is a DM-specific antibody and patients are at 
increased risk of malignancy; it was shown that patients with anti-155 kD antibodies 
have a 89% specificity and 78% sensitivity of developing cancer-associated DM 
(Trallero-Araguas et al, 2010). Recently, it was shown that anti-p155/140 target a 
family of proteins called TIF1 (transcriptional intermediary factor-1), which is are 
involved in several pathways including carcinogenesis (Targoff, 2008, Betteridge et 
al, 2009; Gunawardena et al, 2009). Anti-p155 specifically targets a TIF1-y, a 
nuclear protein involved in cell differentiation (Gunawardena et al, 2009).  
 
Anti-NXP-2 (formally anti-MJ) antibodies target another 140 kD protein that was 
subsequently identified as nuclear matrix protein 2 (NXP2). NXP2 is a nuclear 
protein involved in gene transcription. Anti-NXP2 is associated with severe muscle 
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weakness, contractures, calcinosis, intestinal vasculitis and polyarthritis. These 
antibodies are found in JDM, DM and PM and are usually associated with a younger 
age of disease onset, however patients generally have a good response to treatment 
(Gunawardena et al, 2008, 2009).  
 
Anti-SAE antibodies target a 40 kD and 90 kD proteins that was subsequently 
identified as being a small ubiquitin-like modifier activating enzyme 1 and 2 
(SAE) which are involved in post-translational modification of various targets 
(Betteridge et al, 2009, Gunawardena et al, 2009). Patients with anti-SAE present 
with DM and a specific clinical phenotype characterised by of widespread skin 
involvement, muscle involvement, dysphagia and other systemic features. Anti-SAE 
antibodies were found to have a strong association with HLA-
DRB1*04/DQA1*03/DQB1*03 haplotype (Betteridge et al, 2009; Guawardena et al, 
2009; Chinoy et al, 2009).  
 
Myositis Associated Autoantibodies (MAA)  
 
 Anti-URNPs family  
 Anti-PM-Scl  
 Anti-Ro/SSA  
 Anti-Ku  
 
MAA have been mainly described in scleroderma and overlap syndromes, and have 
been described also in association with some cases of anti-ARS negative IIMs with 
ILD (anti-PM-Scl, anti-U1-RNP, anti-U2-RNP and anti-U5-RNP) (Betteridge et al, 
2009; Gunawardena et al, 2009; Troyanov et al, 2014).  
 
Anti-U-RNP antibodies are a family of antibodies that target small nuclear 
ribonucleoproteins (snRNP) that are important in processing pre-mRNA. Anti-U1-
RNP is generally found in patients with mixed connective tissue disorder, 
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scleroderma or systemic lupus erythematosus (Ihn et al, 1999; Targoff, 2002).  
 
Anti-PM-Scl antibodies target a nucleolar macromolecular complex of peptides of 
which play a role in RNA processing; the main PM-Scl antigens are a 100 kD protein 
and a 75 kD protein (Targoff, 2002). These antibodies are detected in patients with 
IIM, isolated systemic sclerosis or overlap scleroderma/myositis.  Patients generally 
present with prominent arthritis and other systemic involvement such as Raynaud’s 
phenomenon or ILD (Targoff, 2002; Troyanov et al, 2014).  
Anti-Ro/SSA antibodies are among the most frequently detected antibodies 
targeting extractable nuclear antigens (ENA). They are mainly detected in patients 
with systemic lupus erythematosus and Sjögren syndrome, and can be found also in 
other autoimmune diseases like systemic sclerosis, PM, DM, mixed connective 
tissue disease and rheumatoid arthritis (Franceschini & Cavazzana, 2005).  
Anti-Ku antibodies target a DNA binding protein (Ku70/Ku80) involved in DNA 
repair, gene transcription, gene recombination and telomere protection. Anti-Ku 
antibodies have been detected in various autoimmune conditions which include 
systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disorder, 
idiopathic lung fibrosis and scleroderma/myositis (Targoff, 1993; Belizna et al, 2010). 
Patients usually present with muscular and joint symptoms and Raynaud’s 
phenomenon. Unlike ILD in patients with anti-Ku antibodies, musculoskeletal 
symptoms generally respond well to treatment (Targoff, 1993; Belizna et al, 2010).  
 
Novel Myositis Autoantibodies  
 
Anti-cN1A or NT5C1a antibodies (previously identified as anti-Mup44) target the 
cytosolic 5’-nucleotidase 1A, which is part of a family of enzymes that is involved in 
the regulation of intracellular nucleotide pools, energy balance, cell metabolism and 
cell replication (Careddu et al 2008, Kulkarni et al 2011).  
Recently these antibodies were found to be prevalent in sIBM patients (Larman et al, 
2013; Pluk et al 2013), however, a more recent study detected the same antibodies 
also in 4-21% of DM patients and in patients with connective tissue disorders and no 
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myositis, like systemic lupus erythematosus and Sjögren syndrome. These recent 
findings reduce the initial excitement since anti-NT5C1a is not only specific to sIBM 
and cannot be use as a biomarker (Lloyd et al, 2015).   
Anti-3-hydroxyl-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) - Statins 
are drugs usually prescribed to lower blood cholesterol levels and they are 
commercially available since 1987. Necrotising myopathy is amongst the side effects 
of high doses administration of statins that have been reported, and is characterised 
by muscle pain, weakness and tenderness of proximal limbs and axial muscles, 
moderated to markedly elevated serum CK levels, EMG changes, MHC-I expression 
in necrotic muscle fibres and MAC deposits on scattered non-necrotic muscle fibres 
(Le Quintrec & Le Quintrec, 1991; Gaist et al, 2001; Lahaye et al, 2014). Unlike other 
IIM, necrotising myopathy is characterised by little to no inflammatory infiltrate 
(Hamann et al, 2013). A mean incidence of 2.3 per 10000 persons/years has been 
reported in a large UK cohort between 1991 and 1997 (Gaist et al, 2001).  
In 2010, the presence of antibodies directed against 3-hydroxyl-3-methylglutaryl-
coenzyme A reductase (HMGCR), which is the target enzyme of statins, has been 
described (Christopher-Stine et al, 2010). This immune-mediated necrotising 
myopathy is responsive to immunosuppressive treatment. The antibody targets a 
100/200 kD protein complex and is highly specific for this type of myopathy, though 
rare (Mammen et al, 2011). Its presence is also associated with myalgia, arthralgia 
and dysphagia (Mammen et al, 2011).  
HMGCR is a ~ 97 kD membrane protein composed of a small extracellular domain 
(N-terminus), seven membrane spanning domains and an intracellular catalytic 
domain (C-terminus). The antibody specifically recognizes the C-terminus of the 
enzyme (Mammen et al, 2011). The 100 kD protein has been demonstrated to be the 
HMGCR antigen while additional analyses have hypothesized that the 200 kD could 
be an HMGCR dimer (Mammen et al, 2011). Further studies suggested that statins 
up-regulate HMGCR expression thus triggering the autoimmune response. High 
levels of HMGCR in regenerating muscle fibres may perpetuate the immune 
response even after discontinuation of the therapy (Mammen et al, 2011).  
HMGCR antibody was also described in patients that had previously no exposure to 
statins, suggesting genetic predispositions to develop these antibodies.  
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HMGCR antibody was further described in a small cohort of white and African-
American patients, and a strong correlation between anti-HMGCR antibody and 
HLA-DRB1*1101 was reported as a risk factor. The same study proved that DQA1 
and DQB16 were protective factors (Mammen et al, 2011; Gaudet et al, 2012). A 
genome-wide association study has shown a strong association of necrotising 
myopathy with the single nucleotide polymorphism rs4149056 C allele of the 
SLCO1B1 gene on chromosome 12. This gene encodes OATP1B1, an organic 
anion-transporting polypeptide, which regulates the hepatic uptake of drugs; this 
association increases the risk of statin-induced myopathy (SEARCH Collaborative 
group et al, 2008). However, the prevalence of this SLCO1B1 polymorphisms in 
patients with HMGCR antibodies is similar to the general population (Mammen et al 
2011).   
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Immunogenetics of IIM 
 
The cause of IIM remains still unsolved and various hypotheses have been raised 
over the years. It has been suggested that disease expression is triggered by a 
combination of environmental and/or genetic causes in genetically predisposed 
individuals (Prieto & Grau, 2010). Furthermore a correlation between higher 
prevalence of IIM and African-American and Caucasian populations has been 
reported as previously discussed, so studies have been conducted to analyse the 
possible role of genetic factors in the diseases.  
A recent study performed low to high-resolution genotyping to define the possible 
role of HLA (class I: HLA-A, -B, -Cw; class II: HLA-DRB1 and –DQA1) alleles as 
predisposing or protective factor for IIM (O’Hanlon et al, 2005).  
TNFα-308A polymorphism is also predisposing factor which has been reported in 
DM and PM patients (Dalakas & Hohlfeld, 2003; O’Hanlon et al, 2005). Among all 
the pro-inflammatory cytokines that have been described, TNFα performs quiet a 
remarkable role in protein catabolic process: it may induce protein loss via oxidative 
activation of NF-kB (myogenic transcription factor Nuclear Factor Kappa B). 
Furthermore, a link between TNFα-308A and HLA-B*08 has been previously 
reported by Chinoy and co-workers who demonstrated that HLAB*08/TNFα-
308A/DRB1*03/DQA1*05/DQB1*02 haplotype is a risk factor for all subgroups of 
IIMs (Chinoy et al, 2007). This ancestral haplotype has been further analysed for 
possible association with anti-Jo1 or anti-PM-Scl autoantibodies: a strong 
association between DPB1*0101 and anti-Jo1 antibody has been observed while no 
statistical significance has been reported for the association between the allele and 
anti-PM-Scl antibody. DPB1*0101 is associated with DRB1*0301 and only when 
both alleles are present, DPB1*0101 is considered a risk factor for IIM, in contrast 
DRB1*0301 remains an important risk factor even in the absence of DPB1*0101 for 
anti-Jo1 positive patients.  
Another haplotype that confers risk for developing both anti-Jo1 and anti-PM-Scl 
antibodies is DRB1*0301/DPB1*0401 (Chinoy et al, 2009), while DRB1*0302 has 
been demonstrated to be a risk factor for developing anti-Mi-2 autoantibody in 
African American patients (Chinoy et al, 2011).  
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In a further more recent study, Chinoy and co-workers analysed NF-kB 
polymorphisms that could be involved in the pathogenesis of IIM but no significant 
data has been reported (Chinoy et al, 2012). Other cytokines that have been 
investigated for having a role in IIM susceptibility are INFγ and IL-4. INFγ is a Th1 
cytokine that strongly induces MHC-I expression in IIM patients, as previously 
discussed while IL-4 is a Th2 cytokine which functions as B-cell growth factor.  
A genetic association analysis has been performed in a UK Caucasian cohort where 
significant data has been reported only for INFγ: the main INFγ associations with the 
disease have been observed in the microsatellite marker where C(14) repeat 
represents a risk factor specifically for anti-U1-RNP positive patients. These 
associations are independent from HLA-II alleles (Chinoy et al, 2007).  
The presented data thus seems to demonstrate that there is a strong relationship 
between HLA haplotype and IIM even though it has been hypothesized that a 
combination of more than 25 genes, epigenetic and stochastic events associated 
with sufficiently environmental exposure are required for developing an autoimmune 
disease (O’Hanlon et al, 2005). To unravel the complexity of IIM immune-pathogenic 
mechanisms many efforts and years of study are still necessary.  
 
Therapeutic options for IIM  
 
Treatment of IIM aims to modulate or suppress the inflammatory reaction, restore 
muscular activity and prevent extramuscular organs involvement.  
DM and PM generally are responsive to immunosuppressive therapy while sIBM is 
known to be resistant, although an initial mild response may be observed in some 
cases. Ideally, the immunotherapy should be a targeted choice of drug focus on the 
inflammatory component driving the disease (Gordon et al, 2012). Several new 
drugs are being trialled or released on the market, however at present the first 
choice relies on older drugs.  
Steroids, namely prednisone or prednisolone, are the first choice to be started at 
high dose of 1mg/kg/day (maximum 60-80 mg/day). The dosage is the reduced after 
4 weeks down to the lowest dose necessary to control symptoms. Patients that do 
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not respond after the third month of treatment are likely to be non-responsive to 
steroids and treatment should be discontinued by tapering down the drug.  
Steroid sparing agents such as methotrexate, azathioprine, mycophenolate mofetil 
and cisclosporin are used in addition to low dose steroids in order to achieve greater 
immunosuppression minimizing steroid induced side effects (Dalakas, 2011).  
Methotrexate is an immunosuppresant agent which inhibits DNA and RNA synthesis 
by antagonizing folate metabolism. Folate is required for the synthesis of thymidine 
which itself is required for DNA synthesis. Methotrexate is started at 7.5mg per week 
and increased gradually after 3 weeks up to 15 – 20 mg per week. Compared to 
other steroid sparing agents its action is faster and therefore preferred, but side 
effects can be more severe. Hepatotoxicity, ulcerative stomatitis, low white blood 
cells, gastrointestinal symptoms, fatigue and fever are the most common side effects 
(Dalakas, 2011; Marie & Mouthon, 2011; Brandao & Marinho, 2011).  
Azathioprine is an antipurine antimetabolite and acts by inhibiting an enzyme, 
amidophosphoribosyltransferase, required for DNA synthesis. Azathioprine is used 
at a dosage up to 3mg/kg/day and usually it takes at least 6 months to kick in. Most 
common side effects are gastrointestinal side effects, skin rash and fatigue (Dalakas, 
2011; Marie & Mouthon, 2011; Brandao & Marinho, 2011).  
Mycophenolate mofetil is like azathioprine an antipurine antimetabolite, however 
compared to azathioprine it works faster though is more expensive. Mycophenolate 
mofetil inhibits the production of new B- and T-cells, hence when used in 
combination with prednisone both auto-reactive existing and new lymphocytes are 
targeted. Mycophenolate mofetil is used at a dose of 2-3 g per day. The most 
common side effects include gastrointestinal symptoms, joint pain, fatigue and 
headache (Dalakas, 2011; Marie & Mouthon, 2011; Brandao & Marinho, 2011).   
Ciclosporin lowers the T-cell activity and compared to the above-mentioned 
immunosuppressants it has a higher toxicity and requires close monitoring of the full 
blood count, kidney and liver function. Ciclosporin works faster than azathioprine and 
mycophenolate mofetil and is used at a dose of 150 mg bi-daily. Side effects 
encountered with cisclosporin are gastrointestinal symptoms, hypertension, fever, 
confusion, sensorineural symptoms, dyspnoea and convulsions (Dalakas, 2011; 
Marie & Mouthon, 2011; Brandao & Marinho, 2011).   
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In severe cases where steroid treatment has failed to induce remission of symptoms, 
intravenous immunoglobulins (IVIg) are used alone or in addition to steroids.  IVIg 
are used at 2g/kg over 2-5 days every 4-6 weeks depending on individual clinical 
response (Dalakas, 2011).  
For refractory patients further drugs should be considered, however diagnosis should 
be revisited before administering more aggressive drugs or new biologicals. New 
biologicals are drugs that target B cells, T cells, T cell migration, complement, TNF-
alpha, IL1 receptor and cellular adhesion molecules. Several of these new 
biologicals have been trialled already and approved in other immune driven 
conditions like multiple sclerosis. The muscle biopsy can help in directing the choice 
of which monoclonal antibody to use depending on the predominant inflammatory 
component (Dalakas, 2011; Marie & Mouthon, 2011; Brandao & Marinho, 2011).  
IBM represents a challenge in terms of treatment, as it is known to be poorly if not 
responsive at all to steroids and other immunosuppresant drugs. This could be 
attributed to the nature of the pathology found in sIBM which is both an inflammatory 
T cell-mediated component alongside a degenerative component. An initial response 
to steroids can be observed however the disease continues to slowly progress and 
so far none of the drugs has proven to be effective in treating this insidious disease 




AIM OF THE STUDY 
 
Idiopathic Inflammatory Myopathies are a heterogeneous group of acquired diseases 
characterised by inflammation of the skeletal muscle with the most common forms 
being sIBM,  DM, PM, overlap syndormes and necrotising myopathy. Sporadic IBM 
is the most common acquired myopathy over the age of 50 years, however despite 
huge efforts in identifying its cause, the pathogenesis of sIBM remains largely 
unsolved and there is still debate on whether it is a primary inflammatory or a 
degenerative condition with secondary inflammatory component.  
Aim of this study was to identify molecules of interest that may shed light on the 
pathogenesis of sIBM by applying a recently developed mathematical model to 
process and analyse expression microarrays, called Chromowave (Turkheimer et al., 
2006), to analyse already published mRNA expression datasets of sIBM, DM and 
PM available in GEO (www.ncbi.nlm.nih.gov/GEO.com).  
During the first phase of the study, the revision of patients diagnosed with IIM 
between 2001 and 2011 at Charing Cross Hospital allowed me to identify three 
patients with an sIBM-like phenotype which have been further investigated for their 
peculiar phenotype. Analysis of their sera allowed identification of a novel 
autoantibody and its target. This finding prompted me to develop a diagnostic test to 





STRUCTURE OF THE STUDY 
 
Chapter 1 - Chromowave analysis of already published expression datasets allowed 
identification of molecules of interest, which was then further investigated on 
selected cases following a revision of patients diagnosed with IIM between 2001 and 
2011 at Charing Cross Hospital.  
 
Chapter 2 - A study on three patients, identified through the audit of IIM diagnosed 
between 2001 and 2011, is reported. The three patients have a very similar 
phenotype and had muscle biopsy features of sIBM, however responded well to 
steroid treatment. Analysis of their sera allowed me to identify a novel autoantibody 
and its target. This finding let to further modelling studies of the antigen.  
 
Chapter 3 - A pilot study for the identification of novel autoantibodies is reported. 
This last part of the project is a result of outcomes reported in chapter 2 and let to 
the filing of a patent to develop a diagnostic method for the identification of novel 



















CHROMOWAVE ANALYSIS OF EXPRESSION MICROARRAY 






INTRODUCTION TO CHAPTER 1 
 
Previous studies described disrupted myonuclear structure in sIBM, suggesting that 
RVs might originate from myonuclear degradation. Greenberg et al. (2006) showed 
the presence of emerin in RVs and Nakano et al. (2008) identified histone 1 and 
emerin in RVs suggesting that nuclear membrane damage could lead to transfer of 
nuclear material to the cytoplasm (Karpati & Carpenter, 1993; Fidzianska et al., 
2008; Nishii et al., 2011). Microarray mRNA expression studies documented up-
regulation of several genes associated with immunoregulatory pathways, cell 
adhesion molecules and the cytoskeletal network in sIBM (Raju & Dalakas, 2005; 
Greenberg et al., 2005; Greenberg, 2007; Parker et al., 2009), but failed to identify 
significant differences between sIBM, PM and DM that could define an expression 
profile characteristic of sIBM.   
 
Turkheimer et al. (2006) have developed a mathematical model called Chromowave, 
to process and analyse expression microarrays. This is a powerful method for 
investigating expression datasets and has recently been applied successfully to the 
analysis of expression changes in human gliomas and Huntington’s disease 
(Anderson et al., 2008).  
I applied Chromowave analysis to expression microarray of sIBM compared to DM, 
PM and normal subjects with the aim to identify candidate genes that may shed light 
on the possible pathogenesis of sIBM. I performed immunohistochemistry, 









Chromowave is a newly developed mathematical model (Turkheimer et al., 2006) 
(written in MATLAB 7, the Mathworks Inc., Natick MA, USA) used to analyse 
expression microarrays.  
Expression microarrays are a standard technique used to quantify gene expression 
in a set of tissues for thousands of genes simultaneously.  
After normalising the microarray to the background, expression values were 
transformed on a log2 scale and mapped to their corresponding chromosomal 
location using the genome alignment information contained in the manifest of each 
platform (http://www.affymetrix.com/support/technical/manual/taf_manual.affx). 
Chromowave uses single value decomposition and Haar wavelets to detect 
variations in expression of spatially related genes and to represent such changes on 
physical maps of chromosomes. A wavelet is a wave-like oscillation and as a 
mathematical function can be used to extract information from different type of data. 
A wavelet transform (WT) is the representation of a function by wavelets. Wavelets 
were introduced for the analysis and encoding of genomic data by Lio (Lio, 2003). 
On the contrary of conventional statistical analysis based on variation in single gene 
expression, Chromowave applies wavelets to explore the variation in expression of 
gene clusters and to identify variation in expression of large regions of 
chromosomes. Chromowave applies the WT to the spatial distribution of the probes 
and converts the original expression values to wavelet coefficients that are functions 
of the expression of adjacent genes. The noise level is identical on the original raw 
data and at all WT levels. This is advantageous because a cluster of genes with 
similar expression is transformed into a WT coefficient that is greater the larger the 
number of genes in the cluster. Therefore the net effect of the application of the WT 
is that genes with individual expression below the noise level, that would otherwise 
go undetected, are identified when clustered together because their combined 
energy condenses into a greater wavelet coefficient that arises over the noise. 
The microarray dataset that analysed global gene expression in muscle samples of 
sIBM, DM, PM patients and controls were taken from published studies that used 
Affymetrix oligonucleotide microarrays (Greenberg et al., 2005; 2007) and is 
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available in the GEO database. The dataset contain n = 21 healthy controls and n = 
23 sIBM samples, n = 6 PM samples and n = 18 DM samples. 
The analysis was performed comparing sIBM to healthy controls, PM to healthy 
controls and DM to healthy controls.  




The patients reported in this study provided written informed consent for the genetic 
tests and functional and immunological analyses. The Ethics Committee of Imperial 
College London (UK) approved the study. 
Ten sIBM cases and 10 PM/DM samples, available at the Imperial College 
Healthcare Tissue Bank London, were selected following an audit of patients with 
diagnosis of IIM between 2001 and 2011. Seventy-five control muscle samples 
(available at Imperial College Healthcare Tissue Bank London) from patients who 
had a muscle biopsy with suspicion of vasculitis and appeared normal at pathological 
examination. All cases have been reviewed by Dr F. Roncaroli to confirm the 
diagnosis.  
Inclusion criteria for selection of sIBM cases: age onset > 50 years; sIBM clinical 
phenotype; normal or CK level lower than 1,000 IU/L; no response to steroids. 
  
Exclusion criteria: high CK level >1000 IU/L; steroid responsiveness; infectious 




I tested anti-emerin antibody (mouse monoclonal, Novocastra, UK) on frozen muscle 
tissue of 10 patients with sIBM, 10 PM/DM and 75 control muscle tissues supplied by 
the Tissue Bank at the Charing Cross Hospital. Ten-micron sections of the frozen 
tissue were incubated with normal horse serum (Invitrogen, USA) (1:10) for 30 
minutes to suppress nonspecific staining and incubated for 1 hour at room 
temperature with anti-emerin antibody (1:200).  After washing with 0.1% PBS/Triton, 
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sections were developed with the Super SensitiveTM IHC Detection System 
(BioGenex, CA).  
RNA and DNA extraction from muscle tissue  
 
RNA and DNA were isolated from frozen muscle tissue. Ten sIBM and ten control 
samples were processed. 
RNA was isolated from tissue using Trizol reagent (Invitrogen, USA). Trizol reagent 
800µl and glycogen (20µg/µl; Invitrogen, USA) 200µl were added to 1 mg of muscle 
tissue and then homogenized using an electronic homogeniser (Wolflabs, UK). 
Following homogenization, samples were centrifuged at 12,000 g for 10 minutes at 
4°C. The supernatant containing RNA was transferred to a fresh tube and 0.2 mL of 
chloroform per 1 mL of Trizol reagent and DNase (Ambion, UK) were added. Tubes 
were shaken by hand for 15 seconds and incubated at 15-30°C for 3 minutes. 
Following centrifugation at 12,000 g for 15 minutes at 4°C, the mixture separates into 
a lower red, phenol-chloroform phase, an interphase, and a colourless upper 
aqueous phase. The aqueous phase, containing RNA, was transferred to a new tube 
and butanol 500 µl was added, mixed and incubated at room temperature for 10 
minutes, then centrifuged at maximum speed for 15 minutes at 4°C. The supernatant 
was removed and ethanol 75% 200 µl was added. Samples were centrifuged at 
maximum speed at 4°C for 10 minutes, ethanol was removed and samples were air 
dried at room temperature. RNA was eluted in 50 µl of distilled molecular water. 
 
DNA was isolated according to the following protocol: Tissue was incubated at 50°C 
in TNE (10mM Tris, 100mM NaCl, 1mM EDTA) 1x/0.5% sodium dodecyl sulphate 
and proteinase K (Invitrogen, USA) (100µg/ml) for one week. Fresh proteinase K 2-5 
µl was added every other day to speed up the digestion. When all tissue was gone, 
phenol 500 µl was added and rotated on the shaking plate for 15 minutes. Samples 
were centrifuged at maximum speed for 20 minutes at room temperature. The top 
aqueous layer was placed in a new tube; RNase A (2mg/ml) 2µl (Qiagen, 
Netherlands) was added and stored at room temperature for 30 minutes. Phenol 500 
µl was added and mixed as above. Samples were centrifuged at maximum speed for 
15 minutes, the top aqueous layer was placed in a new tube and ethanol 100% was 
added. Samples were stored overnight at -20°C and then centrifuged at maximum 
speed for 30 minutes at 4°C. Ethanol was removed and ethanol 70% added. 
  
35 
Samples were centrifuged for 30 minutes, ethanol was removed and samples were 
air-dried. DNA was eluted in 50 µl of distilled molecular water.  
DNA and RNA quantity and quality were assessed using a spectrophotometer 
(NanoVue Plus, GE Healthcare Life Sciences, UK).  
 
Polymerase Chain Reaction (PCR) 
 
To amplify each individual emerin exon (1-6) including the intron/exon boundaries, 
primers were designed from genomic sequence of the emerin gene using the human 
genome browser gateway (http://genome.ucsc.edu/cgi-bin/hgGateway) (Fig.1.1, 
Table 1.1) (Bione et al., 1995).  
PCR was performed in a total volume of 20µl using 100 ng of genomic DNA as 
template and 0.1µl each of forward and reverse primers at a concentration of 
100µmole. Final reagent concentrations in the PCR reaction mixture (1.1x ReddyMix 
PCR Master Mix 1.5mM MgCl2- Thermo Scientific, USA) were ThermoPrime Taq 
DNA Polymerase 0.625 units, Tris-HCl 75mM, (NH4)2SO4 20 mM, MgCl2 1.5mM, 
0.01% Tween 20, dATP, sCTP, dGTP, and dTTP 0.2mM. 
After denaturation at 95°C for 3 minutes, 35 cycles followed each consisting of 95°C 
for 1 minute, 60°C for 1 minute, and 72°C for 90 seconds. Elongation followed at 
72°C for 10 minutes. The PCR products were run in a 2% agarose gel for size 
analysis and in a 0.8% agarose gel for purification. PCR products were purified from 
the gel using NucleoSpin Extract II kit (Macherey-Nagel, Germany). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) primer has been used as control. All 6 exons 
have been amplified for all patients and controls.  
Specific primers to cover the entire first exon, including the 5’-untranslated region (5’-
UTR) have been designed that is otherwise not covered by primers used also for 
diagnosed purpose as this is a CG-rich region and difficult to sequence. AccuPrime 
CG-rich DNA polymerase (Thermo Scientific, USA) was used to amplify the 5’-UTR 







Figure 1.1  
 
Chromosome X graphic illustration from Human genome browser. Red vertical 
bar shows position of emerin gene in Xq28. Below chromosome X, emerin genes 
exons and introns are illustrated. Graphic illustration of emerin gene and region of 
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F: forward; R: reverse 
 
Cloning into chemically competent cells 
 
The purified PCR products of exon 1 have been cloned into chemically competent 




Fifty ng of the purified PCR product were sequenced by the DNA sequencing service 
in the MRC CSC Genomics Core Laboratory (Hammersmith Campus-Imperial 




Mutation interpretation analysis  
 
I used the Alamut software (http://www.interactive-biosoftware.com/alamut.html) to 
interpret genomic mutations.  
 
 
Pathway analysis to identify proteins interacting with emerin 
 
I performed a pathway analysis to identify proteins interacting with emerin using 
String 9.0 database (http://string-db.org/) available online. String is a database 
of known and predicted protein interactions. The interactions include direct and 
indirect associations, derived from four different sources (genomic context, high-








In silico analysis of expression microarray obtained from muscle of patients with PM, 
DM, sIBM and healthy controls, downloaded from GEO dataset 
(http://www.ncbi.nlm.nih.gov/gds?term=myositis) showed a statistically significant 
expression of several genes in sIBM compared to healthy controls (t-test 2.10596E-
07) (Figure 1.1a, b), in PM versus healthy controls (t-test 1.26909E-06) (Figure 1.1c, 
d) and DM versus healthy controls (t-test 1.44259E-05) (Figure 1.1e, f).  
Similarities between the three patterns of Chromowave analysis in sIBM, PM and 
DM microarray, involving mainly chromosome 6, showing predominantly up-
regulations of genes involved in inflammation, were observed and confirmed 
previous reports of up regulation of cytokines, MHC class I and II molecules, 
granzymes, and immunoglobulins. Individual analysis of each gene expression on 
each chromosome compared for the three different conditions analysed allowed me 
to identify a down-regulation of the gene coding for emerin (EMD) in Xq28 in sIBM 
(expression level -0.74) compared to healthy controls and to DM (expression level -
0.002) and PM (expression level 0.009) (Figure 1.2a, b).  
A standard analysis confirmed low expression of EMD gene in sIBM compared to 
healthy controls, PM and DM. 
No difference in expression was found for genes encoding for proteins interacting 


















Table 1.2: Expression of genes encoding for proteins interacting with emerin 
 
















EMD Emerin -0.742974 -0.002 0.009 
LMNA Lamin A/C 0.23814 -0.09 0.003 
BANF1 Barrier-to-
autointegration factor 
0.20859 -0.05 0.009 
LMNB1 Lamin B1 No difference No difference No difference 
BCLAF1 Bcl-2-associated 
transcription factor 1 
No difference No difference No difference 
GUCA2A Guanylin precursor No difference No difference No difference 
LEMD3 Inner nuclear 
membrane protein 
Man1 
-0.082796 0.043 -0.08 
SYNE2 Nesprin-2 -0.12016 0.019 0.002 
LMNB2 Lamin B2 No difference No difference No difference 
LMO7 LIM domain only 
protein 7 














Figure 1.1: Cases obtained from GEO dataset. T-test between (a) sIBM cases 
and healthy control subjects; (c) Healthy controls and PM; (e) healthy controls and 
DM; (b, d, f) chromosomal expression pattern extracted from Chromowave 
analysis respectively for the three different conditions analysed. sIBM versus 
healthy control subjects (b); PM versus healthy control subjects (d); DM versus 
healthy control subjects (f). X-axis: gene distance on every chromosome; y-axis: 
gene differential expression (intensity and direction, log2 scale). In b and d positive 
values represent mRNA down-regulation in sIBM and PM patients respectively, while 
in f positive values represent mRNA up-regulation. Red arrow pointing to the emerin 
































Figure 1.2a: Changes in expression of genes located on chromosome X in 




Figure 1.2b: Comparison of EMD gene expression in sIBM, DM and PM 




Immunohistochemistry and Immunofluorescence 
 
Immunohistochemical and immunofluorescence stains with anti-emerin antibody 
revealed abnormal immunolabelling of emerin in myonuclei of sIBM patients 
compared to control muscle and positive immunolabelling in RVs (Figure 1.3a, b). 
Myonuclei stained with emerin appear like ground glass (Figure 1.3a) in sIBM 
patients. Further to this there is also positive sarcolemmal labelling of emerin in 




Figure 1.3a: Examples of immunoperoxidase staining using anti-emerin 
antibodies (Novocastra 1:100), weak immunolabelling in some nuclei, positive 
immunolabelling in RVs (dotted line highlighting one of the fibres with RVs) in sIBM 
patients asn ground glass appearance of nuclei (arrow) (A) and normal 






















Figure 1.3b: Immunofluorescence study of emerin expression in sIBM (A, B, C) 
and DM (D, E, F), (20x). In E and F a blood vessel shows strong positive 
labelling of nuclei. A & D, Dapi; B & E, anti-emerin antibody (LabVision 1:100); C & 










PCR for genomic DNA using GEMD1-6F/R primers has been performed on all 
patients and controls. For each exon the PCR product was of the expected 
molecular size in all patients (Fig.1.4).  
 
 
Figure 1.4: Agarose gel showing PCR product for exon1-6 of the emerin gene.  
 
Marker  Exon1 Exon2  Exon3  Exon4  Exon5  Exon6    
 
 
Sequencing and mutation interpretation analysis  
 
Sanger sequencing was performed at the MRC CSC Genomics Core Laboratory 
(Hammersmith Campus-Imperial College London). Sequencing of emerin exon 1 
revealed two point mutations (c.1-77C>T and c.1-5C>T) in the 5’-untranslated region 
(5’-UTR) in 2 different clones of patient 1. In silico analysis using Alamut software to 
predict mutation pathogenicity failed to show any predictable consequences.  
 
These results prompted me to further investigate the significance of these mutations. 
I designed further primers to cover the entire emerin gene, including the 5’-UTR. The 
5’-UTR region is a CG-rich region and hence can be particularly difficult to sequence. 
Sequencing of this region was performed initially with the same polymerase used for 
all other sequencing experiments in this section. This was then repeated a specific 
polymerase for GC-rich regions, AccuPrime GC-rich DNA polymerase (Thermo 




Sequencing analysis was then performed on further 5 sIBM, 5 DM/PM and 5 normal 
control subjects. Sequencing analysis revealed single nucleotide substitutions in the 
5’-UTR in all sIBM patients tested, in 3 DM/PM and in none of the healthy controls 
(Table 1.3). No mutations were identified in exon 2-6 of the emerin gene.  
 
 
Table1.3 Sequencing results of the first exon of the emerin gene, including the 
5’-UTR region showed that patients had various SNPs in the 5’-UTR region.  
 
Patient Identified variant in 
5’UTR of EMD gene 
Patient 1 (sIBM) c.1-145A>G 
Patient 2 (sIBM) c.1-125T>C 
Patient 3 (sIBM) c.1-90C>T 
Patient 4 (sIBM) c.1-51T>C 
Patient 5 (sIBM) c.1-63T>C 
Patient 6 (DM/PM) c.1-69C>T 
Patient 7 (DM/PM) c.1-149T>C 





In silico analysis for mRNA secondary structure prediction using GeneBee 
 
In silico analysis using GeneBee database to predict mRNA secondary structure 
changes due to point mutations in -77C>T and -5C>T showed possible secondary 
structure changes (Figure 1.4a, b, c).  
 































Pathway analysis to identify proteins interacting with emerin using String 
database 
 
According to String database emerin interacts directly and indirectly with several 
proteins residing at the nuclear envelope, in the nucleus and cytoplasm (Figure 1.5). 
Predicted functional partners are specified in Table 1.4. 
 
 
Figure 1.5: Emerin close interaction network extracted from String database.  
The different line colours represent the types of evidence for the association. Colour 
legend is reported in the table below. Evidence is in most cases based on 





Table 1.4 Predicted Emerin Functional Partners extracted 
from String database 
         
   
  
 LMNA lamin A/C; lamins are components of the nuclear 
lamina (664 aa) 
        •   •   
0.999 
 BANF1 barrier to autointegration factor 1; plays fundamental 
roles in nuclear assembly and chromatin organisation  
(89 aa) 
        •   •   
0.999 
 SYNE1 spectrin repeat containing, nuclear envelope 1; 
involved in the maintenance of nuclear organisation 
(8797 aa) 
        •   •   
0.979 
 BCLAF1 BCL2-associated transcription factor 1; death-
promoting transcriptional repressor (920 aa) 
        •   •   
0.966 
 LEMD3 LEM domain containing 3; can function as a specific 
repressor of TGF-beta, activin, and BMP (911 aa) 
            •   
0.965 
 LMNB1 lamin B1 (586 aa)         •   •   0.964 
 GUCA2A guanylate cyclase activator 2A (guanylin); endogenous 
activator of intestinal guanylate cyclase  (115 aa) 
            •   
0.960 
 SYNE2 spectrin repeat containing, nuclear envelope 2; 
involved in the maintenance of nuclear organisation 
(6907 aa) 
            •   
0.952 
 STAR steroidogenic acute regulatory protein; plays a key role 
in steroid hormone synthesis (285 aa) 
            •   
0.945 






DISCUSSION TO CHAPTER 1 
 
Changes in emerin gene expression seen in sIBM with Chromowave (Turkheimer et 
al., 2006) analysis and further supported by immunohistochemistry and 
immunofluorescence studies are in agreement with well-known sIBM features like 
morphologically abnormal myonuclei and with previous studies that identified nuclear 
proteins within RVs suggesting a nuclear damage. This finding highlights the 
complexity of sIBM and is consistent with the idea that sIBM is a degenerative 
myopathy rather than a primary inflammatory myopathy.  
Chromowave analysis showed a statistically significant difference between the sIBM 
and control groups. In particular, expression of nuclear envelope protein emerin 
mapping on Xq28 was significantly lower compared to healthy controls and to DM 
and PM. No difference in expression was found for genes coding for the other 
proteins of the nuclear envelope including proteins interacting with emerin. In 
contrast, the expression of gene involved in the inflammatory response, including 
MHC on chromosome 6 was up regulated, as expected. 
 
To look at the localization of emerin in sIBM patients, I then selected 10 biopsies with 
typical features of sIBM, 5 of DM, 5 PM and 75 control muscles from the Imperial 
College Healthcare Tissue Bank. As normal controls, we considered patients who 
underwent a muscle biopsy with a suspicious of vasculitis or with myalgia as only 
symptom but that appeared normal at pathological examination. Cases were stained 
for emerin using immunoperoxidase. Similar to previous studies (Karpati & 
Carpenter, 1993; Askanas & Engel, 2003; Raju & Dalakas, 2005; Greeberg et al, 
2005, 2006; Greenberg 2007; Fidzianska et al, 2008; Nakano et al, 2008; Parker et 
al, 2009; Nishii et al, 2011) and in keeping with in silico analysis, we observed 
abnormal subsarcolemmal and intranuclear localization of the protein and 
accumulation in RVs.  
Previous studies showed cases of X-linked Emery-Dreifuss Muscular Dystrophy, in 
which patients presented a typical pathological picture of sIBM  (inflammatory 
infiltrate, Rvs, amyloid deposits, cytoplasmic and nuclear tubulo-filamentous 
inclusions), suggesting that sIBM pathological aspects are non-specific and probably 




The nuclear envelope (NE) is composed of inner and outer nuclear membranes (INM 
and ONM), nuclear pore complexes and the lamina, a thin fibrous support structure.  
The nuclear lamina and INM proteins are involved in fundamental nuclear activities 
like maintaining and integrating cell shape, anchoring chromatin, association with 
nuclear bodies, localization to and function in sites of DNA replication and mediating 
transcription. The nuclear lamina is composed mainly of nuclear lamins, lamin A type 
and B type (Stuurman et al. 1998). Several proteins have now been identified that 
specifically localize to the inner nuclear membrane. Almost all of the INM proteins 
have a large nucleoplasmic domain capable of binding lamins, chromatin or both. 
The NE has an important physiologic and pathologic role. Indeed, mutations in NE 
proteins are responsible for a group of diseases termed “nuclear envelopathies”. The 
clinical phenotype of these diseases is variable, ranging from cardiac and skeletal 
myopathies and partial lipodystrophy to peripheral neuropathy and premature aging.  
In this project in silico analysis showed low expression of emerin gene in sIBM, 
therefore I performed a pathway analysis using String database to highlight emerin’s 
direct and indirect interactions with other proteins and as expected the interaction 
network is very complex and vast (Figure 1.5). 
Emerin is a 34 kDa, type II integral membrane protein, residing principally at the 
inner nuclear membrane (INM) (Manilal et al., 1998) and belongs to a family of 
nuclear proteins (LAP2, MAN1). Each member of this family has a 40 amino acids 
LEM (LAP2, Emerin, MAN1) domain that binds barrier-to-autointegration factor 
(BAF) (Lee et al., 2001; Haraguchi et al., 2001), a conserved chromatin protein. 
Emerin interacts with proteins that are not only residing at the NE. Table 1.5 





Table 1.5 Proteins interacting with emerin 




Lamins form a stress-resistant structural 
support to the nuclear membranes. 




Nesprin 1 and 2 bind both emerin and 
lamins A/C and form a network linking 
the nucleoskeleton to the INM, the ONM, 
membraneous organelles, the sarcomere 
and the actin cytoskeleton. 
SUN1 and 2 SUN-emerin interaction occurs at the 
INM 
LUMA LUMA is an integral membrane protein 
that spatially and functionally organises 
protein complexes of the INM. LUMA 
interacts with emerin and participates in 
controlling its distribution along the 
nuclear membrane.  
 
β-catenin 
Down-stream target of the Wnt signalling 
pathway. Emerin is responsible for β-
catenin export from the nucleus. 
 
BAF 
DNA binding protein. Binds emerin 
through LEM domain during telophase, 




Cytoplasmic and nuclear protein. 
Interacts with emerin to anchor the 






To date at least 70 different emerin mutations have been published and shown to be 
pathogenic, but mutations in the 5’-UTR has never been described 
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=EMD) perhaps because primers 
generally used for diagnostic do not cover the 5’-UTR.  
Initial sequencing analysis of patient 1 showed two different point mutations in the 5’-
UTR. In silico analysis using Alamut software to predict mutation pathogenicity did 
not show any predictable consequences. However, in silico analysis to predict 
secondary mRNA structure using GeneBee software showed that the mutations may 
possibly affect the secondary mRNA structure and hence translation. Sequencing 
analysis was then performed in 5 sIBM, 5 DM/PM and 5 normal control subjects. 
Sequencing analysis revealed single nucleotide substitutions in the 5’-UTR in 6/10 
sIBM patients, 3 DM/PM and none of the healthy controls. No mutations in exon 2-6 
were found.  
 
The 5’-UTR region is the sequence that extends from transcription start site to just 
before the ATG translation initiation codon (Chatterjee & Pal, 2009). The UTRs are 
highly structured GC-rich sites composed of upstream open reading frame and 
internal ribosomes entry sites. The UTRs are site for protein expression regulation at 
the level of translation. Point mutations and truncations in UTRs may affect 
translation (Chatterjee & Pal, 2009).  
Pathway analysis showed that emerin interacts with β-catenin, which is a down-
stream target of the Wnt-signalling pathway. Previous studies in sIBM suggested 
already a crucial role of the Wnt-signalling pathway in sIBM pathology (Morosetti et 
al., 2008). This pathway is involved in many diseases (i.e. colon cancer); the Wnt-
signal promotes intranuclear translocation of β-catenin where it binds to transcription 
factor proteins and activates a transcription coactivation factor (Cadigan & Peifer, 
2009). Emerin is responsible for β-catenin nuclear export and therefore influences β-
catenin nuclear accumulation and reduced levels of emerin can lead to β-catenin 
nuclear accumulation suggesting a role of the Wnt-signalling pathway in sIBM 
(Markiewicz et al, 2006; Morosetti et al, 2008; Cadigan & Peifer, 2009).  
Intranuclear β-catenin accumulation could be responsible for glycogen synthase 
kinase-3β (GSK3β) dysregulation. Indeed, GSK3β is part of a cytoplasmic 
  
61 
destruction complex and is activated when bound to β-catenin. Dysregulation of 
GSK3β could have a role in β-amyloid accumulation (Morosetti et al., 2008). In order 
to validate these studies and identify a diagnostic marker for sIBM, this pathway was 
explored as a separated project in Dr Roncaroli’s laboratory by an MRes student, 
who I co-supervised, and we performed immunohistochemisty analysis for β-catenin 
on 50 consecutive cases of IIM including 10 sIBM. These immunostains did not 
prove any nuclear accumulation in sIBM patients (data not shown as per Imperial 
College London regulations). This might have been dependant on different technical 
approach since Morosetti and co-workers (2008) performed their studies on cell 
cultures from sIBM patients.  
 
In conclusion, using an in silico approach I tried to identify target molecules that 
could shed light on the pathophysiology of sIBM. In silico analysis of already 
published expression microarray suggested that emerin could be a valid candidate, 
which led me to further explore its expression using immunochemistry and 
sequencing analysis.  
Interestingly, immunochemistry studies revealed abnormal localization of emerin at 
subsarcollemal level, intranuclear level and nuclei showed ground glass appearance 
without the typical rim observed normally with emerin staining. Emerin also stained 
positively in RVs as already reported in previous studies (Fidzianska et al, 2010). If 
further confirmed at larger scale, this finding suggests that emerin staining could be 
used as biomarker for sIBM diagnosis.  
Sequencing analysis of the emerin gene revealed single nucleotide substitutions in 
the 5’-UTR of the emerin gene in all sIBM patients and three disease control subjects 
but none of the controls. As previously mentioned this specific region is usually not 
sequenced for diagnostic purpose. However, in recent years the UTR regions are 
gaining more interest as being responsible for protein expression regulation at 
translation level. Sequencing analysis of a larger sample is needed to further confirm 












IDENTIFICATION OF A NOVEL AUTOANTIBODY AGAINST A 








INTRODUCTION TO CHAPTER 2 
 
IIM are heterogeneous, multi-factorial acquired conditions that can potentially cause 
irreversible muscle damage with resulting long-term and often severe disability. The 
activation of the immune system likely occurs in genetically predisposed individuals. 
More than 50% of individuals with IIM develop myositis specific MSA and MAA 
(Nagaraju, 2005). Although the pathogenic role of recognised MSAs and MAAs 
remains unclear, IIMs patients are increasingly classified by serological status, which 
closely associates with clinical phenotype (Finch, 2006). However, there is 
increasing evidence that IIMs may result from chronic immune activation in 
genetically susceptible subjects following specific but undefined environmental 
triggers (Rothwell et al, 2013). The majority of IIM genetic research is focused on the 
role of the MHC genes and their potential implications in autoantibody generation 
and disease expression. Further studies have also investigated the role of 
polymorphisms in the immunoglobulin genes, pro-inflammatory cytokines, and in 
genes that had been previously reported to have a role in other autoimmune 
disorders (Raju & Dalakas, 2005). 
A revision of the Charing Cross Hospital database of patients with diagnosis of IIM 
between 2001 and 2011 resulted in the identification of three unrelated patients with 
remarkably similar phenotype characterised by symmetrical proximal weakness and 
early involvement of the forearm flexors but with relative quadriceps sparing, high CK 
levels (over 3,000 IU/L) and a muscle biopsy with features of sIBM but good 
response to steroid treatment and plasma exchange.  Immunohistochemistry with 
anti-emerin antibodies showed normal localization. Analysis of their sera revealed 
novel autoantibodies to components of the sarcoglycan complex. Gene analysis of 
the sarcolglycans revealed that the three patients were heterozygous for a missense 
mutation in the β-sarcoglycan gene (c.799C>T) leading to the amino acid 
substitution p.Arg267Cys in the extracellular domain of the protein. Molecular 
modelling of the β-sarcoglycan protein suggests that this substitution causes a 





PATIENTS AND METHODS 
Patients’ phenotype and clinical investigations  
 
All patients provided written informed consent for the genetic tests and functional 
and immunological analyses. The Ethics Committee of Imperial College London 
approved the study. 
The three patients, two Caucasians and one Asian had a similar phenotype with high 
CK values and a muscle biopsy with features of sIBM. Sub-acute onset of 
generalised weakness and early and prominent symmetrical involvement of the 
forearm flexors and sparing of the quadriceps characterised the clinical phenotype of 
these patients. Other variable features included mild orbicularis oculi weakness, 
scapular winging, dysphagia, weakness of the neck muscles and anterior distal leg 
muscles. Muscle MRI of the thighs showed multifocal increased signal intensity, 
particularly in the forearms and proximal and distal leg muscles, on T2 and STIR 
sequences. EMG showed features consistent with an inflammatory response. CK 
levels were elevated at onset to over 2000 IU/L. Immunomodulation was beneficial 
with normalisation of CK and recovery from or stabilisation of weakness. In the 
differential diagnosis, a broad range of conditions from myositis and sIBM in 
particular, to adult-onset myopathies and dystrophies were considered. These 
conditions were however excluded following the results of immunohistochemistry, 
immunoblotting and genetic analysis. Tests for MAA and MSA, which included Jo-1, 
PL-7, PL-12, EJ, OJ, SRP, PM-Scl (75kD and 100kD), Ku, Mi-2β, U1-RNP and 
HMGCR were negative. Anti-NT5C1A antibodies were positive only in patient 1. 
Muscle biopsies showed remarkably similar features. The biopsies were 
characterised by atrophic and hypertrophic fibres, fibre necrosis, florid endomysial 
and perimysial, and perivascular lymphocytic infiltrates and aggregates of plasma 
cells. Some fibres contained RVs. A few COX-negative fibres were identified with the 
combined reaction COX/SDH. No sarcoplasmic inclusions were identified with 
congo-red and crystal violet. Lymphocytic infiltrates were composed of CD4 and 
CD8-positive T-cells in similar number, several CD20-positive B-cells and plasma 
cell infiltrate (CD138). MHC-I expression was ubiquitous and granular deposits of 
membrane attack complex (C5b-9) were present both on the sarcolemma and in 
endomysial capillaries and arterioles. Some fibres contained aggregates of p62. All 
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the other immunostains (dystrophins, caveolin 3, dysferlin, laminin-α2) were within 
normal limits. Double immunofluorescence showed co-localisation of IgG and C5b-9 
on several fibres suggesting an antibody-mediated pathogenesis of the condition 
(Figure 2.1B).  In addition, staining with anti-emerin antibodies, performed on the 
basis of previous results in sIBM patients, showed normal nuclear localisation.  
 
Patient 1. A 43-year-old Caucasian man presented with 18 months progressive 
generalized weakness and mild myalgia. Family and past medical history were 
unremarkable. On examination he had scapular winging, mild weakness of the 
orbicularis oculi, neck flexion and extension weakness (MRC 4/5), symmetrical limb-
girdle weakness (4-/5) with clinically spared quadriceps, moderate finger flexor and 
mild foot dorsiflexion weakness. CK was 4000 IU/L (normal 40-320 IU/L). The patient 
responded well to prednisolone (60mg/day) and azathioprine (150mg/day). The 
steroid dose was tapered over 6 months and discontinued completely after 17 
months.  
At 6 months, CK was normal but reduction of the steroid dose resulted in CK 
increase and the re-emergence of the same pattern of weakness as previously, with 
particularly marked wasting of the forearm flexors (Fig. 2.1A), and distal leg 
weakness with bilateral foot drop.  
Three years from presentation, CK was 1446 IU/L. He had generalised upper limb 
weakness and wasting and bilateral foot drop.  Prednisolone and azathioprine were 
re-introduced. Six months later, CK was normal and proximal strength much 
improved. Review of the muscle pathology prompted a trial of plasma-exchange 
(PE), which produced further improvement in muscle strength. 
He has since then remained on prednisolone (5mg/day) and azathioprine 
(100mg/day) and his strength and function has not deteriorated. His CK remains 
moderately elevated (520 IU/L).   
 
Patient 2. A 76-year-old Caucasian woman presented with a 5-month history of 
progressive, symmetrical proximal limb and axial weakness. Family and past medical 
history were unremarkable. On examination, she had symmetrical generalised limb 
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and axial weakness (4/5). CK was 2200 IU/L. She responded well to prednisolone 
(0.8mg/kg/day) and methotrexate (20mg/week) but axial weakness persisted. She 
began to develop finger flexor weakness and wasting, and mild weakness of foot 
dorsiflexion. Methotrexate dose was further increased to 25 mg/week. On review 
after 8 months treatment, proximal limb strength remained normal but symmetrical 
weakness and wasting affecting wrist and finger flexors and extensors (4/5) was now 
more apparent. The patient has remained on weekly methotrexate and prednisolone 
(6mg/day) and her disease remains stable to date (6 years), with CK 300 IU/L.   
 
Patient 3. A 44-year-old Asian woman presented with an 18-month history of 
dysphagia, progressive proximal weakness of the legs and generalised arm 
weakness. There was a family history of diabetes and Raynaud’s phenomenon. On 
examination, she had mild weakness of the orbicularis oculi, neck flexion and 
extension weakness, symmetrical proximal arm weakness, weakness of the forearm 
flexors, and hip flexion weakness (4/5), but quadriceps strength was normal. CK was 
3832 IU/L. She responded well to prednisolone (60mg/day) and azathioprine 
(150mg/day). On a review at one month, the dysphagia had resolved and limb 
strength had largely recovered. Following review of the muscle pathology, she 
underwent PE, with further improvement in muscle strength. One month later, 
muscle strength was normal except in triceps and finger flexors (4-/5). She was 
maintained on prednisolone (15mg/day) and azathioprine (150mg/day). Three 
months later, her strength and function had remained stable and CK was normal.  
One year later, CK increased (574-900 IU/L) and she developed predominantly distal 
limb weakness.  A course of IVIg (40g/day for 5 days) produced improvement. The 




Myositis specific and associated antibodies line blot 
 
To detect MSA and MAA, the sera were tested with a line-blot immunoassay system 
(Euroimmun, Luebeck, Germany). The system is able to detect IgG antibodies to the 
following 11 MSAs and MAAs: Jo-1, PL-7, PL-12, EJ, OJ, SRP, PM-Scl (75kD and 
100kD), Ku, Mi-2β, U1-RNP. 
Sera were incubated with a strip coated with parallel lines of highly purified 
recombinant or native. If specific antibody is bound to an antigen, the bound 
conjugate is visualised by the presence of a coloured product at the location of the 
antigen.  
Anti-HMGCR and anti-NT5C1A antibodies were tested in Dr A Pestronk’ laboratory.  
Anti-HMGCR were negative in all three patients, while anti-NT5C1A were positive 
only in patient 1 and negative in patient 2 and 3. 
 
Histochemistry and immunohistochemistry (IHC) 
 
Quadriceps muscle biopsies were frozen in liquid nitrogen. Ten micron sections were 
cut and stained with haematoxylin and eosin, modified Gomori-trichrome, oxidative 
enzymes, Periodic Acid Schiff, oil red oil and NADH. IHC using a standard 
peroxidase technique was performed on frozen sections of the 3 initial biopsies and 
on the follow-up biopsies of patients 1 and 2. Normal control muscle was used as 
positive control. Immunostaining with omission of the primary antibody was 
performed as negative control. A standard peroxidase IHC technique was used to 
test the patients’ sera (diluted 1:100) against five samples of frozen and formalin 
fixed and paraffin embedded normal control muscle made available by the Imperial 
College Healthcare Tissue Bank London, UK. In addition to the staining performed 
as part of the routine diagnostic service, additional staining with α- β-, γ- and δ-
sarcoglycans  (1:40, 1:50, 1:30, 1:40, mouse monoclonal, Novocastra, UK) and anti-






IF using a standard technique was performed on frozen sections of the 3 initial 
biopsies and on the follow-up biopsies of patients 1 and 2. Immunostaining with 
omission of the primary antibody was also performed as negative control. Sections 
were incubated with anti-C5b-9 (1:30, mouse monoclonal, Novus Biologicals, USA) 
for 1 h. After washing with PBS, slides were incubated with anti-human IgG (Heavy 
and light chain) (1:200, Alexa Fluor 488, Invitrogen, USA) and anti-mouse polyclonal 
IgG (1:200, Alexa Fluor 555, Invitrogen, USA). Slides were mounted with mounting 
medium and 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Vector Labs, 
USA). 
 
Western blot analysis 
 
I performed a one-dimensional 12% SDS-polyacrylamide gel electrophoresis of 
muscle proteins extracts and recombinant α-, β-, γ- and δ-SG (full-length 
recombinant protein with glutathione S-transferase tag, (GST-tag) at N-terminal) 
(Abnova, Taiwan). The gel was electroblotted onto nitrocellulose (Invitrogen, USA). 
To prevent non-specific binding, blots were blocked for 3 hours at 4°C in blocking 
buffer (5% dry non-fat milk/0.1% Tween/PBS) (Tween20 for electrophoresis, Sigma, 
USA).  
Western blot on muscle protein extracts 
 
I tested the patients’ sera (1:1000) on extracts of human normal control muscle, and 
human skeletal muscle membrane and cytoplasmic lysate (Abcam, UK). A healthy 
control serum and omission of patients’ sera were used as negative controls. After 
washing with 0.1% Tween/PBS, membranes were incubated with byotinilated anti-
human IgG and IgM (1:10000) (Vector Laboratories, USA) for 1 hour at room 
temperature. After washing, membranes were incubated with avidin-biotin 
peroxidase complex (Vectastain ABC complex, Vector Labs, USA) for 45 minutes, 




Western blot on recombinant sarcoglycans 
 
The three patients’ sera, including pre- and post-PE sera, and additional 30 sera 
from a Swedish cohort (MyoNet) (diluted 1:1000), were tested against recombinant 
SGs. A healthy control serum and omission of patients’ sera were used as negative 
controls. Anti- anti-α-, β-, δ - and γ-SGs (1:100) (Novocastra, UK) were used as 
positive control. After washing, membranes were incubated with horseradish 
peroxidase conjugated anti-human IgG/M (1:10000) (Abcam, UK) for 40 minutes at 
room temperature. After washing, membranes were exposed to enhanced 
chemiluminescence reagent (ECL Prime Western Blotting Detection Reagent, GE 
Healthcare) and developed.  
Western blot for anti-α-, β-, δ - and γ-SGs antibodies on patients’ samples 
 
Protein extraction from normal control and patients’ muscle samples was performed 
using Radioimmunoprecipitation assay (RIPA) buffer and a protease inhibitor. 
Samples were squashed mechanically, heated for 3 minutes at 90°C and centrifuged 
at 14000 rpm for 10 minutes. The same procedure was repeated 3 times. Protein 
concentration was determined with the Bradford method using bovine serum albumin 
as a standard (BioRad Protein Assay Kit, Germany).  
Nitrocellulose membranes were incubated with anti-α-, β-, δ- and γ-SGs antibodies, 
according to Anderson & Davison, 1999. After incubation, membranes were washed, 
incubated with anti-mouse polyclonal immunoglobulins (1:1000) (Dako, UK) for 40 
minutes at room temperature, washed again, and developed using an ECL Western 
blotting detection system (GE Healthcare, UK). 
Gene analysis for α-, β-, γ- and δ-SGs 
 
Genomic DNA of the 3 patients was extracted from blood using the E.Z.N.A.TM Blood 
DNA kit (OmegaBiotek, USA) according to the manufacturer’s instructions. The four 
genes were sequenced at Northern Genetics Molecular laboratory at The 
International Centre for Life (Newcastle upon Tyne, UK). Genomic DNA was also 
isolated from frozen muscle by phenol extraction and ethanol precipitation. The 
quality and quantity of DNA were assessed by spectrophotometer. Sanger 
sequencing analysis was then repeated in the laboratory.  
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Primers for SGCB and the biotinilated oligonucleotide probe recognising the 
mutation revealed by the initial gene analysis (forward primer 5’-
GGTCAGCACCACTCGCCTA-3’ and reverse primer 5’-
CCACAGGGGTTGTCTGAGAT-3’; wt-probe 5’BIO-AGCACCACCCGCCTACCCA-3’; 
m-probe 5’BIO-AGCACCACCTGCCTACCCA-3’) were designed using 
http://frodo.wi.mit.edu/primer3/ and purchased from Invitrogen (USA). Genomic DNA 
amplification was performed in a 20µL reaction at 50°C and 30 cycles using 100ng of 
DNA template, 0.1 µL forward and reverse primers (100 µmole) respectively, and 
18.8 µL of ReddyMix buffer (Thermo Scientific, USA).  
The PCR product was visualised on an ethidium-bromide stained 0.8% agarose gel 
and purified using the Nucleo Spin Extract II (Macherey-Nagel, Germany) according 
to the manufacturer’s instructions.  
The gel was blotted on a positive charged nylon membrane (Ambion, USA) using a 
passive capillary transfer and alkaline buffer. The membrane was then incubated 
with the biotinilated probe (100 µM, 1:6000) overnight at 45°C on a shaking plate. 
The membrane was then developed with a chromogenic kit (ThermoScientific, USA) 
according to manufacturer instructions. 
Modelling of β-sarcoglycan 
 
To the best of my knowledge the three-dimensional structure of β-SG has not yet 
been resolved by X-ray crystallography or NMR spectroscopy. A PSI-BLAST 
analysis using the amino acid sequence of this protein did not reveal the presence of 
homologous proteins of known structure. Therefore, I used the fold recognition 
algorithm implemented in I-TASSER (Zhang, 2008; Roy et al, 2010; Yang & Zhang, 
2015) (iterative threading assembly refinement algorithm) to predict a 3D model of 
both wild type (wt) and mutated (m) β-SG. To obtain a more reliable structure 
prediction of these membrane proteins, the amino acidic sequences were split into 
two domains: intracellular-transmembrane domains (residues 1-86) and extracellular 
domains (residues 87-318), which included the site of the mutation found in the initial 
sequencing. The domain boundaries of β-SG sequence were obtained from UniProt 
web site (UniProt Consortium, 2014). 
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The disulphide bonds between the cysteine residues of extracellular domain of the 
wild-type (wt) and m β-SG were predicted by the DiANNA (DiAminoacid Neural 
Network Application) algorithm. For the extracellular domain of the wt protein the 
disulfide bonds between Cys288 and Cys314 and between Cys290 and Cys307 
were used as restraints in the I-TASSER structure assembly simulation. For the 
extracellular domain of m β-SG two models (m1 and m2) were built; in m1 the 
residue of Arg267 was substitute with the Cys267 and the same disulfide bonds of wt 
(Cys288-Cys314, Cys290-Cys307) were used as restraints whereas in the m2 two 
different disulfide bonds were used as restraints, Cys267-Cys290 and Cys288-
Cys307, as predicted by DiANNA algorithm relative to the mutant Arg267Cys of β-
SG. 
The best-scored model structure obtained by the I-TASSER prediction of each 
protein domain (intracellular-transmembrane, wt extracellular domain, m1 
extracellular domain and m2 extracellular domain) was chosen for the molecular 
dynamics simulation of β-SG. 
The N-glycosilation sites of β-SG were analysed using bioinformatic analysis that 
confirmed the presence of three glycosylation sites located in the extracellular 
domain at positions Asn158, Asn211 and Asn258. 
Molecular Dynamics Simulation 
 
We performed three atomistic 20ns MD simulations of wt, m1 and m2 β-SG starting 
from the structure of domains obtained from I-TASSER as described above. Initially, 
the models of intracellular-transmembrane and extracellular domains were 
equilibrated separately to relax the structure and subsequently the proteins were 
reconstituted by merging of the domains.  
The model of intracellular-transmembrane domains of β-SG was embedded in a pre-
equilibrated dimyristoyl-sn-glycero-3-phosphocholine (DMPC) bilayer, consisting of 
275 molecules, using the INFLATEGRO program (Schmidt & Kandt, 2012). The 
transmembrane domain was oriented with the axis of α-helix parallel to the normal of 
lipid bilayer and translated along this axis to have the residue of Leu75, central 
residue of transmembrane domain, in the middle region of the bilayer. 
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The systems 3, 
and the proper number of chloride ions was added to preserve electroneutrality. In 
addition, NaCl was added (150 mM) to simulate physiological conditions. The 
systems were energy minimized and equilibrated for 10 ns at 310 K. 
The models of the extracellular domain of wt, m1 and m2 β-SG were solvated in 
three rectangular boxes with a minimum distance between the protein and the box 
wall of 1.0 nm and in the presence of chloride ions and NaCl 150 mM. After 8 ns of 
equilibration the residues of asparagine were glycosylated and the proteins were 
solvated in new rectangular boxes. Each system, consisting of glycosylated 
extracellular domain and water, chloride ions and NaCl 150 mM was energy 
minimized and then equilibrated for additional 6 ns. 
The equilibrated structures of extracellular domains were merged to the intracellular-
transmembrane domain and embedded in lipid bilayer to obtain the initial structure of 
wt, m1 and m2 β-SG for the molecular dynamics simulations. Each protein, 
nm3, neutralized by adding chloride ions in the presence of NaCl 150 mM. 
All MD simulations were carried out with GROMACS v.4.0.5 package, using the 
GROMOS G53a6 force field for proteins and ions in conjunction with the Berger 
force field for the lipids. 
Titratable residues of proteins were modelled according to their protonation state in 
water at pH = 7. 
The glycans GlcNAc2Man8, linked to residues of asparagine, were modelled with the 
G53a6 force field. Water was modelled with the SPC (Simple Point Charge) model. 
Lennard-Jones and electrostatic interactions were calculated using a cut-off of 1.2 
nm and the long-range electrostatic interactions were accounted by using the particle 
mesh Ewald method (PME). 
All bonds were constrained using the LINCS algorithm whereas the geometry of 
water molecules was fixed with the SETTLE algorithm. 
The simulations were carried out with a time step of 2 fs in the isothermal-isobaric 
(NPT) ensemble. The simulated systems were warmed up with five consecutive 
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unrestrained MD from 100 K to 310 K in 50 ps. The temperature of protein, lipids, 
water and ions was kept constant separately at 310 K using the velocity rescale 
method with a time constant of 0.1 ps. The pressure was controlled in the first 2 ns of 
equilibration using the Berendsen barostat (P = 1 bar, τp = 1.0 ps) after which the 
Parrinello-Rahman barostat (P = 1 bar, τp = 4.0 ps) was used to produce the correct 
ensemble. The pressure coupling was isotropic in the case of the simulations in 
water and semi-isotropic in the presence of the lipid membrane. Periodic boundary 
conditions were applied in all three dimensions. 
The root-mean square fluctuation (RMSF) was calculated for the Cα atoms of the 
three different domains of the protein. The RMSF of the intracellular and extracellular 
domains increased rapidly in the first nanoseconds of simulation, and then reached a 
plateau within the first 10 ns. On this basis, the last 10 ns of the trajectories of wt, m1 
and m2 β-SG were used for the analysis of the proteins structure. 
The trajectory analysis was performed using the tools in the GROMACS package. 
Analysis of the secondary structure was performed with the program DSSP. VMD 
was used for trajectory visualization and graphical structure analysis. 
Table 2 Summary of simulated systems 
Protein 





Number of Ions 
β-SG wt +5 35579 131 Na+, 
136Cl- 
β-SG m1 +4 35579 131 Na+, 
135Cl- 
β-SG m2 +4 35612 131 Na+, 
135Cl- 
 
Alignment of the extracellular amino acid sequence of β- with γ- and δ-SG 
 
Alignment of the extracellular amino acid sequence of the 3 SGs using the Basic 
Local Alignment Search Tool (BLAST) showed homology and similarity of different 
regions (Fig. 2.5). Interestingly, the SNP c.799C>T in the β-SG induces a 
substitution p.Arg267Cys which increases the homology of β-SG with γ-SG in that 
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region. I have also aligned homologue and similar amino acid of the extracellular 
domains of wt and m1 β-SG models in order to calculate most likely target sequence 







Analysis of patients’ sera 
 
To understand if the inflammatory response was driven by autoantibodies other than 
the known MSA and MAA, I then tested the serum of the three patients against 
sections of normal muscle and observed that positive immunolabelling of the 
sarcolemma suggesting an immune reaction against a sarcolemmal antigen. No 
immunoreactivity was conversely observed in the sarcoplasm and myonuclei. 
I then investigated the patients’ sera against lysates of whole muscle proteins 
extracted from a control sample and normal sarcolemma and sarcoplasm (Abcam, 
UK). The sera of ten healthy volunteers were also tested as controls. This 
experiment showed that patients’ sera contained autoantibodies against a 
sarcolemmal antigen of about 35 kDa while none of the controls showed any 
immunoreactivity (Fig 2.3A,B).  
From the molecular weight I hypothesized the ?, ?- and ?-sarcoglygans (SGs) 
could be the most likely target proteins. I therefore tested the sera of patients (1 and 
3) and healthy control against the four full-length recombinant SGs (Abnova, Taiwan) 
and confirmed autoantibodies against ?-, ?- and ?-SG (Fig 2.3C). In contrast, no 
band was identified in the blot with recombinant α-SG. No auto-antibodies were 
detected with the sera collected after PE (Fig 2.3D) but notably, the serum of patient 
3 tested 6 months after PE showed a weak positive reaction suggesting reactivation 
of the immune response against the ?-, ?- and ?-SGs. 
 
Frequency of anti-β-, γ-, δ-SG autoantibodies in other inflammatory 
myopathies 
 
I tested 30 additional sera from a Swedish myositis patient cohort (MyoNet – Global 
Myositis Network) against recombinant SGs. Twenty were seronegative for the 
known MAAs and MSAs and 10 had anti-Jo1 antibodies. Two seronegative and one 
Jo-1 positive patient had antibodies against β-, γ-, δ-SGs (Fig.2.3E, F). ASO-PCR 
and sequencing analysis showed that these three patients were also heterozygous 
for the β-SG mutation (c.799C>T) (Fig. 2.3G). 
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Immunohistochemistry and immunoblotting for SG and filamin C 
 
IHC and immunoblotting with anti-α-, β-, γ- and δ-SG antibodies (mouse monoclonal, 
Novocastra, UK) showed normal SG expression in all patients (Fig. 2.1B and 2.3).   
Immunohistochemistry for filamin C 
 
IHC for filamin C (rabbit anti-human FLNC; Sigma, USA) revealed abnormal 
subsarcolemmal distribution in several fibres in all 3 patients (Fig. 2.1B), possibly 
consequent to a conformation change in the SG complex. 
Genetic analysis of the sarcoglycans 
 
These results prompted me to sequence the genes of the four SGs using genomic 
DNA from blood and DNA from muscle biopsies. A heterozygous missense mutation 
c.799C>T (p.Arg267Cys) in the β-SG gene was found in the three patients by 
Sanger sequencing. In silico analysis (Alamut Mutation Analysis Software-Interactive 
Biosoftware and PolyPhen-2 Software-Polymorphism Phenotyping) predicted that 
the mutation might be pathogenic. This variant has been reported previously in the 
Leiden Muscular Dystrophy database in one patient but no clinical data are available. 
Further to this result, we performed an ASO-PCR using a wt and an m 5’-biotinilated 
oligonucleotide probe against genomic DNA extracted from the 3 patients and 16 
healthy control subjects showed that all three patients but none of the 16 controls 
were also heterozygous for this mutation. 
 
Protein modelling and p-BLAST 
 
In order to understand the impact of p.Arg267Cys on the structure of β-SG I 
performed in collaboration with a colleague, Dr Stefano Borocci from Universita’ della 
Tuscia, Viterbo (Italy), protein modelling of the β-SG.  Using a bioinformatics 
approach we obtained the 3D model of wt β-SG and two models (m1 and m2) for the 
mutation p.Arg267Cys. The residue 267 is close to the cysteine-rich motif and the 
substitution p.Arg267Cys introduces a potential site for the formation of disulfide 
bond. Actually, the model m2 was built to evaluate the effect of the disulfide bond 
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between Cys267 and Cys290 located in the cysteine-rich motif and involved in the 
native disulfide bridge Cys290-Cys314. To evaluate the effect of this mutation on the 
structure and dynamics of β-SG we performed MD simulations (Figure 2.4). This 
showed that the mutation affects mainly the extracellular domain of the protein, 
causing a conformational change and may affect the motility of the intracellular 
domain (Fig.2.4). RMSF of the Cα carbon atoms with respect to their average 
position over the MD trajectory was used as means to evaluate the structure 
flexibility of the proteins. Residues with large value of RMSF are more mobile with 
respect to residues with low value of RMSF (Fig. 2.4A and 2.5).  A p-BLAST of the 
extracellular amino acid sequence of the β/γ/δ-SGs shows different regions of 













Figure 2.1 Representative patient and muscle biopsy
A: Patient 1, two years from presentation, showing scapular winging, forearm flexors 
wasting and relative quadriceps sparing. 
  
 
B: Peroxidase IHC and IF on frozen and formalin fixed muscle samples.  
(H&E) Variation in fibre size, atrophic and hypertrophic fibres, necrotic fibres and 
florid endo- and perimysial lymphocytes (CD4; CD8; CD20), and plasma cell infiltrate 
(CD138). Some fibres contained rimmed vacuoles (Gomori-Trichrome). Several 
COX-negative fibres were present (COX-SDH). There were p62 inclusions in some 
fibres. There was ubiquitous sarcolemmal expression of MHC-I antigen (MHC-I) and 
non-ubiquitous C5b-9 deposits on sarcolemma and endomysial arterioles and 
capillaries (C5b-9, Double IF anti-h-IgG -Alexa Fluor 488-and C5b-9- Alexa Fluor 
555). γ-SG (Novocastra, UK) shows normal level of expression. FLNC (Sigma-
Aldrich, USA) showed abnormal subsarcolemmal accumulation of FLNC in several 




















Figure 2.2 IHC and IF using patient’s serum as primary antibody 
A: The serum of patient 3 incubated on sections of control muscle decorates the 
sarcolemma of several fibres (immunoperoxidase – x20) 
B: sera from normal controls do not show any immunoreactivity (immuoperoxidase – 
x20).  
C – D: Immunofluorescence demonstrates IgG (C) but not IgM deposits (D) on 
muscle tissue from patient 1.  









Figure 2.3 Western blots
Western blot (WB) study of sera. One-dimensional 12% SDS-PAGE of normal 
muscle protein extracts and recombinant SGs (Abnova, Taiwan) were electroblotted 
onto nitrocellulose (Invitrogen, USA) and the membranes were blotted with patients’ 
and control sera as primary antibody, followed by anti-human IgG antibody.  
A: WB of patients‘ sera and control serum (1:1000) tested against whole skeletal 
muscle proteins. Patients’ sera showed a positive 35kDa band (arrows). Omission of 
serum and control serum were used as negative control.  
B: WB on human skeletal muscle membrane (M) and cytoplasmic (C) lysate (Abcam, 
UK). Lane 1: Molecular weight markers. Lanes 2-3 were incubated only with 
secondary antibody and omission of serum; lanes 4-5 were incubated with serum of 
patient 3 (diluted 1:4000). Positive band around 35 kDa (arrow); lanes 6-7 were 





C: WB on recombinant α, β, γ, δ-SG (Abnova, Taiwan) patient 1 and 3’s serum 
(1:1000) showed positive reaction for both β, γ, δ- recombinant SG  
C (Patient 1)   (Patient 3)  
D: WB on recombinant γ- and δ-SG (Abnova, Taiwan). Lanes 1-2 were incubated 
with pre-PE serum; lanes 3-6 were incubated with serum obtained immediately after 
PE; lane 7 was incubated with 6 month post-PE serum. All sera were diluted 1:1000. 
 
  
E: WB with one of the Jo-1 positive MyoNet sera tested on recombinant γ- and δ-SG 
showed positivity for recombinant γ- and δ-SG. 
E       
F: WB with two of the MyoNet sera tested against recombinant α, β, γ, δ-SG, 
showed positivity against γ- and δ-SG. For positive control the recombinant δ-SG 
protein was tested with anti-δ-SG antibody (Novocastra, UK).  
 
 
G: WB with anti-α, β, γ, δ-SG antibodies (Novocastra, UK) on muscle extracts from 





I: Genomic DNA was extracted from peripheral-blood leukocytes and frozen muscle. 





Figure 2.4 Protein modelling 
A: Snapshots after 20ns of MD simulation of β-SG wt (I), m1 (II) and m2 (III). The 
proteins were embedded in a DMPC bilayer consisting of 275 molecules, in the 
presence of water, chloride ions to preserve the electroneutrality and NaCl (150 mM) 
to simulate physiological conditions. 
The proteins are shown as ribbons coloured by secondary structure: red; α-helices, 
yellow; β-strands, cyan; loops. The residue 267 (Arg or Cys) is shown in space-filling 
model (spheres), the glycans and the cysteines of the two disulfide bonds are shown 
as sticks. The ammonium head groups of DMPC lipids are shown as sticks to 
indicate the position of the bilayer.  
Structure of the extracellular domain of β-SG wt (IV), m1 (V) and m2 (VI).  
Backbone representation of β-SG wt (VII), m1 (VIII) and m2 (IX). The line thickness 
and the colour scale (blue-green-red) represent the RMSF of the backbone atoms of 
protein.  
The analysis of wt β-SG secondary structure showed β-strands organised in β-
hairpin motifs in the extracellular domain and an α-helix in the transmembrane region 
(IV). 
The model m1 (V) maintains the main secondary structure of the wt β-SG, however, 
significant changes were observed (arrows). Interestingly, the structural changes 
induced by the mutation concern also regions far from the site of mutation as the 
region from the residue 153-160 (circle). The simple amino acid substitution 
Arg267Cys in m1 affects the structure of extracellular domain (V) and the mobility of 
protein (VIII). It is worth to note that in m1 the intracellular domain is less mobile 
compared to wt (VII, VIII).  
The structure of m2 (VI) is more compact with a reduced number of β-strands with 
respect to wt with a reduced mobility of the extracellular domain and an increased 
mobility of the intracellular domain with respect to wt protein (IX).   
The analysis of RMSF of wt β-SG shows that the β-strands structures are stable with 
a low flexibility, whereas some loops connecting the β-strands are more flexible. In 
particular, the loop formed by the residues 266-276 has the highest mobility (VII). 
Residues with large value of RMSF are more mobile with respect to residues with 
low value of RMSF. 
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B: Alignment of homologue and similar amino acid of the β/γ/δ-SGs of the 
extracellular domains of wt and m1 SG models.  Ribbon and transparent surface 
representation for the extracellular domain of wt and m1 β-SG after 20ns of MD 
simulation. Homology and similarity are represented in different colours of surface 
according to the degree of homology (see legend). Wt and m1 models are displaced 










Figure 2.5 RMSF 
 
A: The RMSF comparison between β-SG wt and β-SG m1 models showed a 
reduced flexibility of the intracellular domain and increased mobility of the 
extracellular domain in m1. The residues 233-234 and the cysteine-rich motif 
(residues 285-318) are more mobile in m1 in respect to wt. The loop 266-276 is the 
region with the highest RMSF in both m1 and wt. 
B: The RMSF comparison between β-SG wt and β-SG m2 models showed an 
increased mobility of the intracellular domain and reduced mobility of the 
extracellular domain in m2.  
 
Figure 2.6  
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P-BLAST of the extracellular amino acid sequence domain of the β/γ/δ-SGs. 
Amino acids are highlighted in different colours according to different grades of 







DISCUSSION TO CHAPTER 2 
 
Reviewing the clinical database of patients with diagnosis of IIM between 2001 and 
2011 at Charing Cross Hospital resulted in the identification of three unrelated 
patients with heterozygous missense mutation c.799C>T in the gene encoding β-SG, 
causing the amino acid substitution p.Arg267Cys. The patients developed an 
inflammatory myopathy associated with autoantibodies directed to β/γ/δ-SG. Protein 
modelling suggested that this substitution causes a conformational change of the 
extra-cellular domain of β-SG suggesting that the conformational change confers 
susceptibility to develop a pathogenic immune response against muscle fibres. For 
the first time, this study suggests that genes encoding structural proteins of skeletal 
muscle represent a novel class of susceptibility genes for IIMs.  
The clinical phenotype of the three patients is characterised by sub-acute onset of 
generalised weakness and early and prominent involvement of the forearm flexors, 
suggestive of sIBM but with relative clinical sparing of the quadriceps. Variable 
features included mild orbicularis oculi weakness, dysphagia, and weakness of the 
neck and anterior compartment distal leg muscles.  Furthermore, CK levels were 
raised at above 2000 IU/L at presentation, not typical of sIBM, and 
immunomodulation produced clear clinical benefit, with normalisation of CK levels.  
Muscle biopsies showed remarkably similar features that were reminiscent of sIBM 
including rimmed vacuoles and p62 sarcoplasmic inclusions but also florid B-
lymphocytes and plasma cells. Although there were sIBM-like pathological features, 
there was also clear evidence of a humoral component with florid endo- and 
perimysial T- and B-cell inflammatory infiltrate, plasma cells and deposits of C5b-9 
on sarcolemma and endomysial capillaries (Fig. 2.1B) suggesting an innate and 
humorally mediated immune response. B-cell and plasma cell infiltrates have been 
demonstrated in sIBM and PM along with local production of immunoglobulins (Ig) 
suggesting a B-cell permissive microenvironment characterises IIMs. The evidence 
of IgG sarcolemmal deposits in our patients, their co-localization with C5b-9 is in 
keeping with an antibody-mediated process and strongly supports the pathogenic 
role of the autoantibodies identified in our patients. These observations are in 
keeping with recent studies that emphasized the role of B-lymphocytes and plasma 
cells in IIMs, and documented a B-cell permissive microenvironment in myositis. IF in 
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our cases showed co-localization of anti-human IgG with deposits of C5b-9 on the 
sarcolemma of many of the muscle fibres, strongly supporting the pathogenic role of 
the antibodies and consistent with the favourable response to PE.  
This evidence along with the absence of known MSA and MAA led me to test further 
the serum of the three patients.   
Analysis of patients’ sera by immunohistochemistry and western blot allowed me to 
identify autoantibodies directed against the β/γ/δ-SGs. Sequencing analysis of the 
four SGs showed that the patients were heterozygous for the missense mutation 
(c.799C>T, p.Arg267Cys) of the β-SG. Interestingly, a subsequent survey of 
samples from patients in the MyoNet database revealed three further patients with 
anti-SG antibodies carrying the same mutation in the β-SG gene while no anti-SG 
were found in normal healthy controls. One of the patients of the MyoNet cohort with 
anti-SG antibodies tested also positive for anti-Jo1 suggesting that identification of 
anti-SG does not exclude the presence of other MSAs.  
The present study is the first to identify a missense mutation in a structural 
sarcolemmal protein that appears to endow antigenicity and trigger an immune 
response. The mutation has been previously reported in the Leiden Muscular 
Dystrophy Database but the clinical phenotype is not reported. I performed an ASO-
PCR on further 16 controls which were negative for the mutation c.799C>T.  In silico 
analysis using PolyPhen and Alamut predicted the change to potentially affect the 
structure of β-SG but immunostains and WB showed normal expression and normal 
sarcoplasmic localisation of the four SG proteins. In addition, no changes were found 
in the expression of proteins related to SGs apart from focal subsarcolemmal 
accumulation of filamin C in some damaged fibres. 
To explore further the impact of p.Arg267Cys on the conformation of β-SG, I 
performed, in collaboration with a colleague, Dr Stefano Borocci, from Universita’ 
della Tuscia, Viterbo (Italy), a 3D molecular modelling of the protein using a 
bioinformatics approach.  
SGs are transmembrane glycoproteins forming a complex with the dystrophin-
associated glycoprotein complex. The assembly of the SG complex follows a specific 
pathway where the formation of β/δ-SG core structure is a critical step and its 
disruption affects the SG complex targeting to the sarcolemma. With the exception of 
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α-SG, the SGs consist of a short intra-cellular domain, a single transmembrane 
region and a large extracellular domain containing a carboxyl-terminal cluster of 
highly conserved cysteine residues forming intra-molecular disulphide bonds. The 
intracellular domain of γ/δ-SG can associate with FLNC while β-SG binds dystrophin. 
Structural characteristics suggest that the SG complex might be involved in signal 
transduction from the extracellular to the intracellular region (Barton, 2006; 
Constantin, 2013). The interaction of both γ- and δ-SG with FLNC provides a direct 
structural link from the SGs to the actin cytoskeleton and to the signal transduction 
pathway associated with FLNC.  
According to the MD simulation, the substitution p.Arg267Cys induces a 
conformational change in the extracellular domain of β-SG. The conformational 
change of the m1 extracellular domain also affects some regions of the amino acid 
sequence far from the site of mutation (residues 153-160) and produces a major 
exposure of the cysteine-rich loop, which is also more mobile than in the wt.  
Cysteine-rich motifs are found in different extracellular proteins and are highly 
conserved throughout different species. The cysteine-rich domain of the β-SG 
belongs to the epidermal growth factor-like family and appears to be important for 
membrane targeting but not for protein-protein interaction (Chen et al, 2006; Draviam 
et al, 2006). These conformational changes may expose an epitope that triggers an 
autoimmune reaction towards β-, γ-, δ-SG. Δ- and γ-SG share 70% homology and 
50% homology to β-SG while α-SG differs considerably from these three proteins. 
Alignment of the extracellular amino acid sequence of β- with γ- and δ-SG showed 
homology of specific regions (Fig. 2.6).  
The m1 MD simulation showed that the substitution p.Arg267Cys also influences the 
mobility of the intracellular domain, which is less mobile than in the wt. Change in 
mobility may explain subsarcolemmal deposition of FLNC in some fibres. The m2 
MD simulation conversely showed major conformational changes in the extracellular 
domain of the protein with reduced extracellular mobility and increased mobility of 
the intracellular domain. Given the entity of change, I think that it is unlikely that a 
protein with such structure might reach the sarcolemma as the β-SG structure 
integrity is crucial for its’ targeting to the membrane surface and for the β-δ-SG core 
formation (Draviam et al, 2006). 
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The identification of a novel autoantibody to structural sarcolemmal proteins in 
patients with IIM and a mutation in the β-SG, together with the observation of a B-cell 
permissive microenvironment, suggests and emphasises that the 
immunopathogenesis of some IIMs can involve both cytotoxic and humoral elements 
acting in concert.  Although Stuhlmüller et al. described antibodies to a 50 kDa 
sarcolemmal protein in patients with polymyositis in 1996, using skeletal muscle 
extract as the antigen source (Stuhlmueller et al, 1996), this protein was not further 
characterised. Antibodies to sarcolemmal proteins have also been identified in other 
immune disorders, notably myasthenia gravis but also in myocarditis (Lindstrom et 
al, 1976; Pankuweit et al, 1995). In addition, there are very rare cases of immune-
driven myopathies with antibodies to muscle extracellular matrix components (al-Lozi 
et al, 1995 and 1997; Yabe et al, 2002). 
 
This study opens new frontiers to the understanding of the pathogenesis of IIM and 
their treatment, and emphasises the importance of careful analysis of muscle tissue 
to determine the elements involved in the immunopathogenesis in individual cases, 
since patients who exhibit a significant humoral element to the disease will likely 
respond to immunosuppressive therapies such as PE and IVIg as adjuncts to the 
standard interventions of steroids and immunosuppressant drugs. The use of B-cell 

















IDENTIFICATION OF NOVEL AUTOANTIBODIES TO 
SARCOLEMMAL PROTEINS IN IIM: A PILOT STUDY 
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INTRODUCTION TO CHAPTER 3 
 
The previous identification of a novel autoantibody to sarcolemmal proteins, against 
three components of the sarcoglycan complex, in three patients led me to test sera 
of a further small number of consecutive patients with a query diagnosis or confirmed 
diagnosis of IIM and control subjects against recombinant sarcoglycans and other 
sarcolemmal proteins. The muscle biopsies of the selected patients were 
characterised by inflammatory infiltrate composed of T-cells and B-cells as well as 
deposits of MAC on sarcolemma and/or endomysial capillaries.  
The recombinant sarcolemmal proteins were selected from those commercially 
available from Abnova (Taiwan).  These were α/β/γ/δ sarcoglycans (α-SG, β-SG, γ-
SG, δ-SG), caveolin 3 (CAV3), sarcospan (SSPN), fukutin related protein (FKRP) 
and laminin-α2 (LAMA2) (Table 3.2). A western blot with recombinant proteins was 
performed; proteins were blotted on a nitrocellulose membrane and then incubated 
with patients’ sera used as primary antibody. Anti-human IgG was used as 
secondary antibody.   
Aim of this pilot study was to identify novel autoantibodies to sarcolemmal proteins. 
Current methods to identify novel autoantibodies in IIM use mainly HeLa extracts as 
antigen source; however, HeLa cells do not express several proteins that are specific 
and selectively expressed in skeletal muscle. In this pilot study I have used 
sarcolemmal proteins in order to identify novel autoantibodies.  




MATERIALS AND METHODS 
 
Patients and Samples 
 
The sera of 10 patients were collected after signed informed consent. All patients 
were referred with either a query diagnosis of IIM or a confirmed diagnosis of IIM. 
Details of patients are reported in Table 3.1. I collected and tested the sera of 9 
healthy individuals after informed consent and used these as control sera.  
 
Table 3.1 Overview of patients’ details.  
Patients Gender Age 
(years) 





F 31 DM >600 azathioprine, 
methotrexate and 
prednisolone 
2 F 63 IBM 751 steroids, methotrexate 
and IVIG 
3 M 63 Rhabdomyolysis  8300 N/A 





5 F 76 IBM 150 mycophenolate mofetil, 
prednisolone, 
azathioprine and IVIG 
6 F 75 IBM + Sjogren’s 
syndrome 
169 azathioprine 
7 M 60 HIV related PM 664 azathioprine, 
prednisolone and IVIG 
8 M 69 Myofibrillar myopathy 700 N/A 











Western blot analysis 
 
I performed a one-dimensional 12% SDS-polyacrylamide gel electrophoresis of 
recombinant α-, β-, γ- and δ-sarcoglycans, caveolin 3, fukutin related protein, 
laminin-α2 and sarcospan (partial and full-length recombinant protein with 
glutathione S-transferase tag, (GST-tag) at N-terminal) (Abnova, Taiwan) (Table 
3.2). One microgramme of protein per well was loaded in each well. The gel was 
electroblotted onto a 0.45 μm pore nitrocellulose membrane (Invitrogen, USA). To 
prevent non-specific binding, blots were blocked for 3 hours at 4°C in blocking buffer 
(5% dry non-fat milk/0.1% Tween/5% Sheep serum/TBS) (Tween20 for 
electrophoresis, Sigma).  
The patients’ and controls’ sera were diluted (1:1000) and tested against the 
recombinant proteins. Healthy control sera were used as negative controls.  After 
washing, membranes were incubated with HRP-conjugated goat anti-human IgG Fc 
(goat) (Rockland, USA) (1:10000, 5% dry non-fat milk/0.1% Tween/1% Sheep 
serum/TBS) for 45 minutes at room temperature. After washing in TBS/T, 
membranes were exposed to enhanced chemiluminescence reagent (Li-Cor, UK) 














Table 3.2 Recombinant sarcolemmal proteins from Abnova, UK. 
 
 
Alignment of sarcolemmal proteins 
 
Alignment of the amino acid sequence of sarcolemmal proteins was performed using 
online available software p-BLAST in order to establish level identity.  
 
 
Protein Features Proteins’ 
concentration 
(μg/μl) 
1 µg per well 
(Volume in μl) 
α-SC: H00006442-P01 GST-Tag full-length 0.34 μg/μl 2.94 μl 
β-SG: H00006443-P01 GST-Tag full-length 0.15 μg/μl 6.67 μl 
γ-SG: H00006445-P01 GST-Tag full-length 0.3 μg/μl 3.33 μl 
δ-SG: H00006444-P01 GST-Tag full-length 0.06 μg/μl 16.67 μl 
CAV3: H00000859-
P01 
GST-Tag full-length 0.09 μg/μl 11.11 μl 
FKRP: H00079147-
Q01 





0.3 μg/μl 3.33 μl 
SSPN: H00008082-
P01 




Patients’ reactivity to recombinant proteins 
This pilot study testing sera of patients with a diagnosis of IIM, including sIBM or 
query IIM against recombinant sarcolemmal proteins by WB showed that 7/10 
patients that were studied had a positive reaction to one or more recombinant 
proteins. In particular, 3/10 patients failed to show any reactivity against the 
recombinant proteins; these patients had a diagnosis of DM, rhabdomyolysis and 
myofibrillar myopathy. Three out of 10 patients were positive for all the sarcoglycans 
and caveolin 3, fukutin related protein and sarcospan; these patients had 
respectively diagnoses of sIBM/systemic lupus erythematosus (SLE) and HIV related 
PM. One out of ten patients had positivity for β- and δ-SG and another patient was 
positive for γ-, δ-SG, caveolin 3, fukutin related protein and sarcospan; they both had 
a query diagnosis of sIBM. While one patient had a positive reaction to β- and δ- SG, 
caveolin 3 and another patient was positive for β-, γ- and δ-SG; both had a diagnosis 
of necrotising myopathy. Of the healthy controls only one patient out of nine showed 
positive reaction to all the sarcoglycans and caveolin 3; this control had been 
previously investigated for systemic lupus erythematosus because of a malar rash 
that is still present. However, none of the investigations confirmed the diagnosis of 
systemic lupus erythematosus. Another control reacted against laminin-α2, however 
the band was not at the expected molecular weight and specificity of this result is 
unclear.  This control had no history of autoimmune disorders. Results of patients’ 
reactivity are summarized in Table 3.3. Immunoreaction is reported as positive 
(POS) or negative (NEG) defined by the presence or absence of a band on the blot; 
in cases where there was a positive band but not at the correct molecular weight this 
was defined as dubious positivity (POS?). Western blots of recombinant 
sarcolemmal proteins blotted with patients/healthy controls are shown in Figure 3.1.  
To note that, two patients (n. 5 and n. 9) had strong reactive bands for some of the 
recombinant proteins, however, these were not at the expected molecular weight. It 
is unclear whether this is a non-specific binding or degradation bands.  
 
Table 3.3 Results of patients’ and healthy controls reactivity to recombinant 
sarcolemmal proteins. Immunoreaction is reported as “positive” or “negative” 
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Patients Recombinant Proteins 
SGCA SGCB SGCG SGCD CAV3 FKRP LAMA2 SSPN 
1 NEG NEG NEG NEG NEG NEG NEG NEG 
2 NEG POS  NEG POS  NEG NEG NEG NEG 
3 NEG NEG NEG NEG NEG NEG NEG NEG 
4 POS POS POS POS POS POS NEG POS 
5 NEG NEG POS? POS? POS? POS? NEG POS? 
6 POS POS POS POS POS POS NEG POS 
7 POS POS POS POS POS? POS? NEG POS? 
8 NEG NEG NEG NEG NEG NEG NEG NEG 
9 NEG POS? NEG POS? POS? NEG NEG NEG 
10 NEG POS POS POS NEG NEG NEG NEG 
Controls  
1* NEG POS POS POS NEG NEG NEG NEG 
2 NEG NEG NEG NEG NEG NEG NEG NEG 
3 NEG NEG NEG NEG NEG NEG NEG NEG 
4 NEG NEG NEG NEG NEG NEG NEG NEG 
5 NEG NEG NEG NEG NEG NEG NEG NEG 
6 NEG NEG NEG NEG NEG NEG NEG NEG 
7 NEG NEG NEG NEG NEG NEG NEG NEG 
8 NEG NEG NEG NEG NEG NEG POS? NEG 
9 NEG NEG NEG NEG NEG NEG NEG NEG 
Positive (POS), negative (NEG), Dubious positivity (POS?)  








Figure 3.1 Western blots of recombinant sarcolemmal proteins blotted with 











































































Frequency of the autoantibodies  
 
In the studied patient cohort the most frequent autoantibodies were β-SG and δ-SG 
(50%), followed by γ-SG (40%), while all the others were found in 20% of the cases, 
apart from antibodies to laminin-α2 that were not found in any of the patients. In 
some cases there was a dubious positivity and this was not considered. Although 
this is only a pilot study and the size of the studied cohort is small, these results 
show that the antibodies to β/γ/δ-SG are the most frequent autoantibodies in patients 
with query IIM or a definite diagnosis of IIM.  
 





Alignments of sarcolemmal proteins  
 
Using online available software (p-Blast) I have aligned the amino acid sequence of 
the proteins to establish identity of their sequences. The p-Blast analysis for 
alignment of two or more amino acid sequences is shown as a result of aligned 
sequences and hits with corresponding scoring. The smaller the E-value, which 
corresponds to the expected number of chance alignments, the better the match. 
This analysis showed that β/γ/δ-sarcoglycans have high homology and identity in 
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their amino acid sequence, while hits between the other proteins did not reveal 




DISCUSSION TO CHAPTER 3 
 
The serological status of IIM patients together with clinic-pathological features is 
becoming more and more important for the classification of IIM. IIMs patients are 
increasingly classified by serological status, which closely associates with clinical 
phenotype. More than 50% of individuals with IIM develop MSA and MAA (Nagaraju, 
2005). Although the pathogenic role of recognised MSAs and MAAs remains unclear, 
identification of autoantibodies can be useful in addressing patients’ individual 
treatment (Finch, 2006). MSA and MAA are mainly being identified by testing 
patients’ sera against proteins extracted from HeLa cell line and only recently other 
types of tissue, like skeletal muscle, is being used. HeLa cells in fact do not express 
several proteins that are tissue specific. As previously reported, recently we have 
identified novel autoantibodies targeting β/γ/δ-sarcoglycans in a small group of 
patients. Sarcoglycans may not be the only antigenic proteins to trigger an IIM. In 
fact, there are previous reports describing antibodies to the sarcolemma (Stuhlmüller 
et al, 1996) in patients with polymyositis; however this was not further characterised. 
Reports of antibodies to sarcolemmal proteins are also well known in other immune 
disorders including myasthenia gravis and myocarditis as well as very rare cases of 
immune-mediated myopathies with antibodies to extracellular matrix components (al-
Lozi et al, 1995 and 1997; Yabe et al, 2002). MSA and MAA reported until now target 
intracellular antigens and interestingly some of these, i.e. Jo-1 and Mi-2, are 
expressed only in myotubes and in regenerating myofibres (Betteridge et al, 2009; 
Gunawardena et al, 2009), suggesting that they do not have a primary role in 
triggering the disease but are rather responsible for secondary events maintaining 
the inflammatory response.  
Prompted by the previously identified antibodies against components of the 
sarcoglycan complex, I tested the serum of further 10 patients with a query diagnosis 
or diagnosis of IIM and 9 healthy controls against several recombinant commercially 
available sarcolemmal proteins.  
Interestingly, the patients that were tested showed variable degree of positive 
reaction against the recombinant proteins, suggesting presence of autoantibodies.  




The most frequent autoantibodies were against the sarcoglycans complex with anti-
δ-SG being the most frequent. Anti-sarcospan antibodies were also relatively 
frequent and always associated with anti-sarcoglycan antibodies. Antibodies to 
caveolin 3 and fukutin related protein were less frequent followed by antibodies to 
laminin-α2. Unexpectedly, among the healthy controls one subject was found to 
have antibodies to the sarcoglycans.  I discovered she had been investigated in the 
past for possible systemic lupus erythematosus for the presence of malar rash, 
which is still present but the diagnosis of SLE is not confirmed.  
A few patients displayed positive bands at a different molecular weight to the 
expected one, whether this is true positivity or reaction or non-specific binding will 
need to be established in further studies with a lager cohort of patients and extended 
analysis. So far this is only a pilot study and false positive should also be considered 
and normal range of positivity will need to be established in further studies.  
Correlation studies between autoantibody frequency in relation to their age or on 
gender predominance has not been performed, as it is difficult for the small sample 
size.  
Alignment of the amino acid sequence of the different proteins using p-BLAST 
showed high degree of identity between SGCB, SGCG and SGCD and less with 
SGCA. SGCB, SGCG and SGCD are aligned for most of their lengths and have 
many identical and positive amino acids in common. For all other proteins no 
significant degree of homology or identity was identified. These data are in keeping 
with results obtained; in fact patients that showed positive reaction to SGCB were 
also positive for SGCG and SGCD.  
In conclusion, this pilot study revealed novel autoantibodies, which may potentially 
be involved in the pathogenesis of IIM. Further studies on larger cohorts and 
functional studies are needed to better understand their role in the pathogenesis of 
IIM and the significance of these findings. If confirmed, these data could have also 
diagnostic and therapeutic implications, as antibodies could be used as biomarkers 






Sporadic IBM is the most frequent inflammatory myopathy above the age of 50 years 
and despite enormous efforts from the scientific community, its pathogenesis  still 
remains a dilemma and it is unclear whether it is a primarily inflammatory disorder 
with secondary degenerative pathological changes or vice versa.  
Over the years the scientific community has invested efforts and resources in order 
to understand pathogenic mechanism of sIBM and in recent years identification of 
novel biomarkers has triggered initial excitement, followed by some disappointment 
since the newly identified autoantibodies, anti-NT5C1a were found not to be solely 
associated to sIBM (Larman et al, 2013; Pluk et al 2013; Lloyd et al, 2015).  
The clinical and pathological heterogeneity of IIMs and in particular of sIBM 
represents a diagnostic and therapeutic challenge for the clinician and specific 
diagnostic markers are needed.  
 
Main aim of this study was to identify molecules of interest that may shed light on the 
pathogenesis of sIBM by applying Chromowave, a recently developed mathematical 
model to process and analyse expression microarrays (Turkheimer et al., 2006), to 
analyse already published mRNA expression datasets of sIBM, DM and PM. When 
selecting patients from the Charing Cross Hospital IIM audit (2001-2011), I identified 
a smaller cohort of three patients that were initially diagnosed as sIBM based on the 
pathological features and some clinical features. Analysis of their sera allowed the 
identification of a novel autoantibody and target which promted additional in silico 
and sequencing analysis, leading to the third part of this report. The third part of this 
report is a pilot study aiming to identify novel autoantibodies in patients with IIM 
using sarcolemmal proteins.  
Patients reported here, identified from the cohort of IIM patients diagnosed and 
followed up at Charing Cross Hospital (Imperial College London), reflect the 
heterogeneity of IIM and the diagnostic challenges and highlight the need for 
validated diagnostic criteria.  
 
In the first part of this study, I tried to identify molecules of interest that may shed 
light on the pathogenesis of sIBM and the re-analysis of already published mRNA 
datasets using a newly developed mathematical model allowed me to identify a 
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nuclear protein, emerin, as a possible key protein in the pathogenesis of sIBM. 
Chromowave analysis showed significant reduced expression of emerin in sIBM. 
Emerin has been previously reported together with other proteins in rimmed 
vacuoles. Immunohistochemistry studies confirmed previous reports, however I also 
observed misplacement of emerin at a sarcolemmal level and at intranuclear level as 
well, making the nuclei appear as ground glass, with less defined nuclear rim. If 
confirmed on a larger scale this observation could be used as a biomarker for the 
diagnosis of sIBM. 
 
Sequencing analysis of the emerin gene of sIBM patients showed various SNPs in 
the 5’UTR of the gene. Although functional studies are needed to prove their 
pathogenicity, it is well known that 5’-UTR regions are crucial site for correct 
processing of the mRNA and point mutations and truncations in UTRs may affect 
translation. In silico analysis using GeneBee software, showed that these mutations 
may affect the secondary mRNA structure. This result could explain the 
mislocalisation of emerin at sarcolemmal level and intranuclear level. Additional 
studies to define the pathogenicity of variants identified in the 5’-UTR of the emerin 
gene are needed for example through a luciferase assay (Wang et al, 2007) since 
the 5’-UTR is not expressed.  
 
Thanks to the revision of a previous audit of IIM patients of the Charing Cross 
Hospital cohort, three patients with sIBM-like phenotype have been identified and 
have been further investigated in view of their unusual phenotype. Further 
investigation of these patients led to the second chapter of this study. Serum 
analysis of these three patients tested against sarcolemmal proteins allowed me to 
identify a novel autoantibody and its antigen. 
Skeletal muscle proteins have rarely been used to identify autoantibodies in IIM, and 
most of the antibodies so far identified are being detected using HeLa cell lysate, 
and notably HeLa cells may not express all muscle specific proteins. In addition, 
most of the known MSA target a cytoplasmic antigen and generally are not 
expressed in adult muscle, suggesting that they are unlikely to be the primary trigger. 
Recently proteins extracted from other types of tissue other than HeLa cell line, are 
being used and allowed the identification of a novel autoantibody anti-NT5C1a 
  
108 
(Larman et al, 2013; Pluk et al 2013). HeLa cells in fact do not express several 
proteins that are tissue specific.  
The serum of these three patients with IBM-like phenotype was blotted against 
sarcolemmal proteins and resulted in the identification of a novel autoantibodies 
targeting β/γ/δ-sarcoglycans. This is the first time that autoantibodies to sarcolemmal 
proteins, the sarcoglycans, have been reported as in association to inflammatory 
myopathy.  The three patients were eventually found to carry a missense mutation in 
the β-sarcoglycan gene which likely triggered an autoimmune reaction since the 
three patients were found to have antibodies targeting the sarcoglycan complex. 
Using an in silico approach we created a β-sarcoglycan protein model to explain 
potential changes to the 3D structure of the protein induced by this mutation.  
 
Sarcoglycans may not be the only antigenic proteins to potentially trigger an IIM. 
Previous reports already described antibodies to the sarcolemma in patients with 
polymyositis, myasthenia gravis, myocarditis and very rare cases of immune-
mediated myopathies with antibodies to extracellular matrix components (al-Lozi et 
al, 1995 and 1997; Stuhlmüller et al, 1996; Yabe et al, 2002). Autoantibodies 
reported until now target intracellular antigens and in some cases are expressed only 
in myotubes or in regenerating myofibres, suggesting that they do not have a primary 
role in triggering the disease but are rather responsible for secondary events 
maintaining the inflammatory response (Betteridge et al, 2009; Gunawardena et al, 
2009).  
 
This striking finding led me to design a pilot study (third part of this report) to study a 
further cohort of IIM patients and control subject and test their sera against 
recombinant sarcolemmal proteins.  
Further analysis of IIM patients’ sera against recombinant sarcolemmal protein 
allowed me to identify positive reaction in some patients suggesting presence of 
antibodies targeting sarcolemmal proteins. Further studies on a larger cohort of 
patients are needed to determine the specificity and prevalence of these antibodies 
are needed. Nonetheless this finding allowed us to file a patent for the development 






Anti NXP2 anti-nuclear matrix protein 2 
Anti-ARSs Anti-aminoacyl-tRNA synthetase  
Anti-CADM-140/MDA5 antibodies anti melanoma differentiation associated gene 5 
Anti-cN1A anti-cytosolic 5'-nucleotidase  
Anti-EJ anti-glycyl synthetase  
Anti-Ha anti-tyrosyl synthetase  
Anti-HMGCR anti-3-hydroxyl-3-methylglutaryl-coenzyme A reductase 
Anti-Jo1 anti-histidyl synthetase 
Anti-KS anti-asparaginyl synthetase 
Anti-OJ anti-isoleucyl synthetase  
Anti-PL12 anti-alanyl synthetase 
Anti-PL7 anti-threonyl synthetase  
Anti-PM-Scl anti-polymyositis-scleroderma 
Anti-SAE small ubiquitin-like modifier activating enzyme 1 & 2  
Anti-SRP signal recognition particle 
Anti-URNPs anti-small ribonucleoprotein 
Anti-Zo anti-phenyalanyl synthetase 
ASO allele specific oligonucleotide 
BLAST Basic Local Alignment Search Tool 
CAV3 caveolin 3  




ECL enhanced chemiluminescence 




FKRP fukutin related protein  
FLNC filamin C 
H&E Hematoxylin and eosin 




IIM Idiopathic inflammatory myopathy 
IL interleukin 
ILD interstitial lung disease 
IM-VAMP inflammatory myopathy – vacuoles, aggegates, mitochondrial pathology 
INM inner nuclear membrane 
IVIg intravenous immunoglobulins 
jDM juvenile dermatomyositis 
LAMA2 laminin-α2  
LDH lactate dehydrogenase 
MAA myositis associated antibody 
MAC membrane attack complex 
MD molecular dynamics 
MHC Major histocompatibility complex 
MSA myositis specific antibody 
NE nuclear envelope 
PCR polymerase chain reaction 
PE plamsa exchange 
PM poymyositis 
PME particle Ewald method 
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RIPA Radioimmunoprecipitation assay 
RMSF Root mean square fluctuation 
RVs rimmed vacuoles 
SDS-PAGE Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
SG sarcoglycans 
sIBM sporadic inflammatory myopathy 
SLE systemic lupus erythematosus 
SPC simple point charge 
SSPN sarcospan  
Tasser Iterative Threading ASSEmbly Refinement 
TNF tumour necrosis factor 
UTR untranslated region 
WB western blot 
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